MariMed (MRMD) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	0-54433
Entity Registrant Name	MARIMED INC.
Entity Central Index Key	0001522767
Entity Tax Identification Number	27-4672745
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10 Oceana Way
Entity Address, City or Town	Norwood
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02062
City Area Code	617
Local Phone Number	795-5140
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		335,793,167

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 33,467	$ 29,683
Accounts receivable, net	3,462	1,666
Deferred rents receivable	1,586	1,678
Notes receivable, current portion	129	127
Inventory	12,238	9,768
Investments	1,253	251
Other current assets	2,179	1,440
Total current assets	54,314	44,613
Property and equipment, net	65,482	62,150
Intangibles, net	2,395	2,230
Investments	100
Notes receivable, less current portion	9,104	8,987
Right-of-use assets under operating leases	4,913	5,081
Right-of-use assets under finance leases	576	46
Other assets	98	98
Total assets	136,982	123,205
Current liabilities:
Accounts payable	8,311	5,099
Accrued expenses	1,728	1,349
Income taxes payable	20,059	16,467
Sales and excise taxes payable	1,355	1,798
Notes payable, current portion	10	10
Mortgages payable, current portion	1,416	1,400
Operating lease liabilities, current portion	1,128	1,071
Finance lease liabilities, current portion	178	27
Other current liabilities		2
Total current liabilities	34,185	27,223
Notes payable, less current portion	46	448
Mortgages payable, less current portion	16,624	16,814
Operating lease liabilities, less current portion	4,343	4,574
Finance lease liabilities, less current portion	372	22
Other liabilities	100	100
Total liabilities	55,670	49,181
Mezzanine equity:
Total mezzanine equity	37,725	37,725
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value; 38,875,451 shares authorized at March 31, 2022 and December 31, 2021; zero shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $0.001 par value; 700,000,000 shares authorized at March 31, 2022 and December 31, 2021; 335,558,206 and 334,030,348 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	336	334
Common stock subscribed but not issued; 2,717 and zero shares at March 31, 2022 and December 31, 2021, respectively	2
Additional paid-in capital	138,064	134,920
Accumulated deficit	(93,204)	(97,392)
Noncontrolling interests	(1,611)	(1,563)
Total stockholders’ equity	43,587	36,299
Total liabilities, mezzanine equity, and stockholders’ equity	136,982	123,205
Series B Convertible Preferred Stock [Member]
Mezzanine equity:
Total mezzanine equity	14,725	14,725
Series C Convertible Preferred Stock [Member]
Mezzanine equity:
Total mezzanine equity	$ 23,000	$ 23,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	38,875,451	38,875,451
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	700,000,000	700,000,000
Common stock, shares issued	335,558,206	334,030,348
Common stock, shares outstanding	335,558,206	334,030,348
Common stock subscribed but unissued	2,717	0
Series B Convertible Preferred Stock [Member]
Mezzanine equity, par value	$ 0.001	$ 0.001
Mezzanine equity, shares authorized	4,908,333	4,908,333
Mezzanine equity, shares issued	4,908,333	4,908,333
Mezzanine equity, shares outstanding	4,908,333	4,908,333
Series C Convertible Preferred Stock [Member]
Mezzanine equity, par value	$ 0.001	$ 0.001
Mezzanine equity, shares authorized	12,432,432	12,432,432
Mezzanine equity, shares issued	6,216,216	6,216,216
Mezzanine equity, shares outstanding	6,216,216	6,216,216

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues	$ 31,282	$ 24,643
Cost of revenues	14,306	11,457
Gross profit	16,976	13,186
Operating expenses:
Personnel	3,042	1,727
Marketing and promotion	643	225
General and administrative	6,228	3,171
Bad debts	14	1,025
Total operating expenses	9,927	6,148
Operating income	7,049	7,038
Non-operating income (expenses):
Interest expense	(313)	(1,512)
Interest income	163	34
Loss on obligations settled with equity		(1)
Gain (loss) on change in fair value of investment	48	(45)
Other investment income	954
Total non-operating income (expenses), net	852	(1,524)
Income before income taxes	7,901	5,514
Provision for income taxes	3,660	1,204
Net income	4,241	4,310
Net income attributable to noncontrolling interests	53	90
Net income attributable to MariMed Inc.	$ 4,188	$ 4,220
Net income per share
Basic	$ 0.01	$ 0.01
Diluted	$ 0.01	$ 0.01
Weighted average common shares outstanding
Basic	334,762,825	305,212,269
Diluted	378,890,365	340,825,940

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Common Stock Subscribed But Not Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 314,000	$ 5,000	$ 112,974,000	$ (104,615,000)	$ (577,000)	$ 8,101,000
Beginning Balance, shares at Dec. 31, 2020	314,418,812	11,413
Issuance of subscribed shares		$ (5,000)	5,000
Issuance of subscribed shares, shares	11,413	(11,413)
Stock grants		$ 5,000				5,000
Stock grants, shares		6,877
Exercise of warrants			8,000			8,000
Exercise of Warrants Shares	50,000
Amortization of option grants			295,000			295,000
Issuance of stand-alone warrants			56,000			56,000
Conversion of debentures payable	$ 5,000		1,351,000			1,356,000
Conversion of debentures payable, shares	4,610,645
Conversion of promissory notes	$ 3,000		1,007,000			1,010,000
Conversion of promissory notes, shares	3,365,972
Common stock issued to settle obligations			31,000			31,000
Common stock issued to settle obligations, shares	42,857
Equity issuance costs			(387,000)			(387,000)
Distributions					(83,000)	(83,000)
Net income				4,220,000	90,000	4,310,000
Ending balance, value at Mar. 31, 2021	$ 322,000	$ 5,000	115,340,000	(100,395,000)	(570,000)	14,702,000
Ending Balance, shares at Mar. 31, 2021	322,499,699	6,877
Beginning balance, value at Dec. 31, 2021	$ 334,000		134,920,000	(97,392,000)	(1,563,000)	36,299,000
Beginning Balance, shares at Dec. 31, 2021	334,030,348
Stock grants		$ 2,000				2,000
Stock grants, shares		2,717
Amortization of option grants			2,469,000			2,469,000
Conversion of promissory notes	$ 1,000		399,000			400,000
Conversion of promissory notes, shares	1,142,858
Distributions					(101,000)	(101,000)
Net income				4,188,000	53,000	4,241,000
Exercise of options			3,000			3,000
Exercise of options, shares	10,000
Fees paid with stock	$ 1,000		273,000			274,000
Fees paid with stock, shares	375,000
Ending balance, value at Mar. 31, 2022	$ 336,000	$ 2,000	$ 138,064,000	$ (93,204,000)	$ (1,611,000)	$ 43,587,000
Ending Balance, shares at Mar. 31, 2022	335,558,206	2,717

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income attributable to MariMed Inc.	$ 4,188	$ 4,220
Net income attributable to noncontrolling interests	53	90
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	702	462
Amortization of intangibles	140	177
Amortization of stock grants	2	5
Amortization of option grants	2,469	295
Amortization of stand-alone warrant issuances		56
Amortization of warrants attached to debt		539
Amortization of beneficial conversion feature		177
Amortization of original issue discount		52
Bad debt expense	14	1,025
Fees paid with stock	274
Loss on obligations settled with equity		1
Gain (loss) on change in fair value of investment	(48)	45
Other investment income	(954)
Changes in operating assets and liabilities:
Accounts receivable, net	(1,810)	(1,691)
Deferred rents receivable	92	64
Inventory	(2,470)	(624)
Other current assets	(739)	(434)
Other assets		(17)
Accounts payable	3,212	1,035
Accrued expenses	217	(129)
Income taxes payable	3,592	1,204
Sales and excise taxes payable	(443)	233
Operating lease payments, net	(6)	(4)
Finance lease interest payments	7	2
Other current liabilities	(2)	(24)
Net cash provided by operating activities	8,490	6,759
Cash flows from investing activities:
Purchase of property and equipment	(4,015)	(2,308)
Purchase of cannabis licenses	(305)	(638)
Investment in Green Growth Group, Inc.	(100)
Interest on notes receivable	43	69
Net cash used in investing activities	(4,377)	(2,877)
Cash flows from financing activities:
Proceeds from issuance of preferred stock		23,000
Equity issuance costs		(387)
Repayments of promissory notes	(2)	(15,801)
Payments on mortgages	(174)	(1,157)
Proceeds from exercise of options	3
Proceeds from exercise of warrants		8
Due to related parties		(132)
Finance lease principal payments	(55)	(10)
Distributions	(101)	(83)
Net cash (used in) provided by financing activities	(329)	5,438
Net change to cash and cash equivalents	3,784	9,320
Cash and cash equivalents at beginning of period	29,683	2,999
Cash and cash equivalents at end of period	33,467	12,319
Supplemental disclosure of cash flow information:
Cash paid for interest	302	1,092
Cash paid for income taxes	68	14
Non-cash activities:
Finance lease right-of-use assets and liabilities	514
Conversion of promissory notes	400	1,010
Conversions of debentures payable		1,356
Operating lease right-of-use assets and liabilities		466
Common stock issued to settle obligations		30
Issuance of common stock associated with subscriptions		$ 5

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	3 Months Ended
	Mar. 31, 2022
Real Estate [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS MariMed Inc. (the “Company”) is a multi-state operator in the United States cannabis industry. The Company develops, operates, manages, and optimizes over 300,000 Upon its entry into the cannabis industry in 2014, the Company was an advisory firm that procured state-issued cannabis licenses on behalf of its clients, developed cannabis facilities which it leased to these newly-licensed companies, and provided industry-leading expertise and oversight in all aspects of their cannabis operations. The Company also provided its clients with ongoing regulatory, accounting, real estate, human resources, and administrative services. Over the last few years, the Company made the strategic decision to transition from a consulting business to a direct owner and operator of cannabis licenses in high-growth states. Core to this transition is the acquisition and consolidation of the Company’s clients (the “Consolidation Plan”). Among several benefits, the Consolidation Plan would present a simpler, more transparent financial picture of the full breadth of the Company’s efforts, with a clearer representation of the revenues, earnings, and other financial metrics the Company has generated for its clients. The Company has played a key role in the successes of these entities, from the securing of their cannabis licenses, to the development of facilities that are models of excellence, to funding their operations, and to providing operational and corporate guidance. Accordingly, the Company believes it is well suited to own these businesses and manage the continuing growth of their operations. To date, the Company’s acquisition and consolidation of its cannabis-licensed clients’ retail businesses in Illinois and retail and wholesale businesses in Massachusetts have been completed. In April 2022, the acquisition of its client’s wholesale business in Maryland, and a third-party wholesale business in Illinois were consummated. The acquisitions of clients’ retail and wholesale businesses in Nevada and Delaware are at various stages of completion and subject to each state’s laws governing the ownership transfer of cannabis licenses and other closing conditions. Delaware will require a modification of current cannabis ownership laws to permit for-profit ownership, which is expected to occur when the state legalizes recreational adult-use cannabis. Until the law changes and the acquisition is approved, the Company continues to generate revenue from rental income, management fees, and licensing royalties. In addition to the aforementioned acquisitions of its cannabis-licensed clients, in February 2022, the Company was notified that it was awarded a cannabis dispensary license from the state of Ohio, for which it had previously applied. The Company is awaiting the final verification process to be completed by the state before commencing cannabis operations in this state. The Company’s transition to a fully integrated muti-state cannabis operator (“MSO”) is part of a strategic growth plan (the “Strategic Growth Plan”) it is implementing to drive its revenues and profitability. The Strategic Growth Plan has four components: (i) complete the Consolidation Plan, (ii) increase revenues in existing states, by spending capital to increase the Company’s cultivation and production capacity, and develop additional assets within those states, (iii) expand the Company’s footprint in additional legal cannabis states through new applications and acquisitions of existing cannabis businesses, and (iv) optimize the Company’s brand portfolio and licensing revenue by expanding into additional states with legal cannabis programs. The Company has created its own brands of cannabis flower, concentrates, and precision-dosed products utilizing proprietary strains and formulations. These products are developed by the Company in cooperation with state-licensed operators who meet the Company’s strict quality standards, including all natural—not artificial or synthetic—ingredients. The Company licenses its brands and product formulations only to certified manufacturing professionals who follow state cannabis laws and adhere to the Company’s precise scientific formulations and product recipes. The Company markets its high-quality cannabis flowers and concentrates under the award-winning 1 1 2 The Company also has strategic alliances with prominent brands. The Company has partnered with renowned ice cream maker Emack & Bolio’s® to create a line-up of cannabis-infused vegan and dairy ice cream. Additionally, the Company has secured distribution rights for the Binske® line of cannabis products crafted from premium artisan ingredients, the Healer line of medical full-spectrum cannabis tinctures, and the clinically-tested medicinal cannabis strains developed in Israel by global medical cannabis research pioneer Tikun Olam. The Company was incorporated in Delaware in January 2011 under the name Worlds Online Inc. The Company’s stock is quoted on the OTCQX market under the ticker symbol MRMD. In April 2022, the Company applied to list its shares of common stock on the Canadian Securities Exchange, which application is currently pending. 1 2

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In accordance with GAAP, interim financial statements are not required to contain all of the disclosures normally required in annual financial statements. In addition, the results of operations of interim periods may not necessarily be indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s most recent audited annual financial statements and accompanying notes for the year ended December 31, 2021. Certain reclassifications may have been made to prior periods’ presentation to conform to the current period presentation. These reclassifications had no effect on previously reported income or cash flows. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at March 31, 2022: SCHEDULE OF MAJORITY OWNED SUBSIDIARIES Subsidiary: Percentage MariMed Advisors Inc. 100.0% Mia Development LLC 89.5% Mari Holdings IL LLC 100.0% Mari Holdings MD LLC 97.4% Mari Holdings NJ LLC 100.0% Mari Holdings NV LLC 100.0% Mari Holdings Metropolis LLC 70.0% Mari Holdings Mt. Vernon LLC 100.0% Mari Mfg LLC 100.0% Hartwell Realty Holdings LLC 100.0% iRollie LLC 100.0% ARL Healthcare Inc. 100.0% KPG of Anna LLC 100.0% KPG of Harrisburg LLC 100.0% MariMed OH LLC 100.0% MariMed Hemp Inc. 100.0% Meditaurus LLC 100.0% Intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions. Cash Equivalents The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values. At both March 31, 2022 and December 31, 2021, cash of approximately $ 5,101,000 was held in escrow, primarily comprised of a $ 5,000,000 escrow deposit in connection with the acquisition of Kind Therapeutics USA LLC as further discussed in Note 3 – Acquisitions The Company’s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the normal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard. Accounts Receivable Accounts receivable consist of trade receivables and are carried at their estimated collectible amounts. The Company provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding balances with consideration towards such client’s historical collection experience, as well as prevailing economic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $ 41.4 million at both March 31, 2022 and December 31, 2021. For further discussion on receivable reserves, please refer to Note 18 – Bad Debts Bankruptcy Claim – Commitments and Contingencies. Inventory Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria. The Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of the date of this report, no reserve was deemed necessary. Investments Investments are comprised of equity holdings in public and private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are deemed to have occurred. Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract with Customers, ● Identify the contract(s) with a customer; ● Identify the performance obligations in the contract(s); ● Determine the transaction price; ● Allocate the transaction price to the performance obligations in the contract(s); and ● Recognize revenue as the performance obligation is satisfied. Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other party—is acting in the capacity as the principal in the sale transaction, and who is the agent arranging for goods or services to be provided by the other party. The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations, and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy. The Company’s main sources of revenue are comprised of the following: ● Product Sales – direct sales of cannabis and cannabis-infused products primarily by the Company’s retail dispensaries and wholesale operations in Massachusetts and Illinois. This revenue is recognized when products are delivered or at retail points-of-sale. ● Real Estate – rental income and additional rental fees generated from leasing of the Company’s state-of-the-art, regulatory-compliant cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts. ● Management – fees for providing the Company’s cannabis clients with comprehensive oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue and are recognized after services have been performed. ● Supply Procurement – resale of cultivation and production resources, supplies, and equipment, acquired by the Company from top national vendors at volume discounted prices, to its clients and third-parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser. ● Licensing – revenue from the sale of Company’s branded products including Betty’s Eddies and Kalm Fusion, and from the sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered. Research and Development Costs Research and development costs are charged to operations as incurred. Property and Equipment Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred. The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years; tenant improvements, the remaining duration of the related lease ; furniture and fixtures, seven to ten years; and machinery and equipment, ten years. Land is not depreciated. The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment loss is measured by the excess of the asset’s carrying amount over its estimated fair value. Impairment analyses are based on management’s current plans, asset holding periods, and currently available market information. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements. In the three months ended March 31, 2022 and 2021, based on the results of management’s impairment analyses, there were no impairment losses. Leases The consolidated financial statements reflect the Company’s adoption of ASC 842, Leases Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Impairment of Long-Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets Fair Value of Financial Instruments The Company follows the provisions of ASC 820, Fair Value Measurement Financial Instruments, Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable, approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by the Company during the three months ended March 31, 2022 and 2021: SCHEDULE OF ASSUMPTIONS USED Three Months Ended 2022 2021 Life of instrument * 3.0 5.0 Volatility factors * 1.230 1.266 Risk-free interest rates * 0.36 0.85 Dividend yield * 0 * No options or warrants were issued by the Company during the three months ended March 31, 2022. The expected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment The Company amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument. Extinguishment of Liabilities The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation, Income Taxes The Company uses the asset and liability method to account for income taxes in accordance with ASC 740, Income Taxes ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no Certain of the Company’s subsidiaries are subject to the provisions of Section 280E of the Internal Revenue Code, as amended, which prohibits businesses from deducting certain expenses associated with the trafficking of controlled substances within the meaning of Schedule I and II of the Controlled Substances Act. Such non-deductibility of certain ordinary business expenses results in permanent differences and can cause the Company’s effective tax rate to be highly variable and not necessarily correlated with pre-tax income. Related Party Transactions The Company follows ASC 850, Related Party Disclosures In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements. Comprehensive Income The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income Earnings Per Share Earnings per common share is computed pursuant to ASC 260, Earnings Per Share At March 31, 2022 and 2021, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock options – convertible into 39,811,671 11,017,750 26,351,571 32,282,708 4,908,333 31,081,080 zero 10,705,513 For the three months ended March 31, 2022 and 2021, the aforementioned potentially dilutive securities increased the number of weighted average common shares outstanding on a diluted basis by 44,127,540 35,613,671 Commitments and Contingencies The Company follows ASC 450, Contingencies If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows. Beneficial Conversion Features on Convertible Debt Convertible instruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging A beneficial conversion feature is a nondetachable conversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic value, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full or partial conversions of the debt. Risk and Uncertainties The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws. Noncontrolling Interests Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets. Off Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements. Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	NOTE 3 – ACQUISITIONS Kind Therapeutics USA LLC In December 2021, the Company entered into a membership interest purchase agreement with the members of Kind Therapeutics USA LLC, the Company’s client in Maryland that holds licenses for the cultivation, production, and dispensing of medical cannabis (“Kind”), to acquire 100 % of the equity ownership of Kind in exchange for $ 13.5 million payable in cash (subject to adjustment) and $ 6.5 million payable by the issuance of four-year 6.0% promissory notes to the members of Kind, secured by a first priority lien on the Company’s property in Hagerstown, MD. Upon execution of the membership interest purchase agreement, the Company deposited, in escrow, the sum of $ 5.0 million as a contract down-payment. In April 2022, the Maryland Medical Cannabis Commission approved the Company’s acquisition of Kind, and the acquisition was consummated by the parties. Accordingly, Kind will be consolidated into the financial results of the Company commencing on the closing date of the acquisition. Following the closing of the transaction, the Maryland litigation between the Company and the members of Kind was dismissed as further discussed in Note 20 – Commitments and Contingencies Simultaneous with the Kind membership purchase agreement, the Company entered into a membership interest purchase agreement with one of the members of Kind to acquire such member’s entire equity ownership interest in (i) Mari Holdings MD LLC (“Mari-MD”), the Company’s majority owned subsidiary that owns production and retail cannabis facilities in Hagerstown, MD and Annapolis, MD, and (ii) Mia Development LLC (“Mia”), the Company’s majority owned subsidiary that owns production and retail cannabis facilities in Wilmington, DE. The purchase price of $ 2 million in the aggregate is expected to be paid, and the transaction consummated, upon the dismissal of the derivative claims in the DiPietro lawsuit in June 2022, as further discussed in Note 20 – Commitments and Contingencies 99.7 % and 94.3 %, respectively. The Harvest Foundation LLC In 2019, the Company entered into a purchase agreement to acquire 100 There is no assurance that the closing conditions to the Company’s acquisition of Harvest, including regulatory approval, will be achieved or that the acquisition will be consummated. The purchase price is comprised of the issuance of (i) 1,000,000 1.2 400,000 Meditaurus LLC In September 2021, the Company acquired the remaining 30.0 100,000 94,000 10,000 70.0 2.8 The carrying value of the noncontrolling interest of approximately $ 975,000 was eliminated on the date such interest was acquired in September 2021, and since there was no change in control of Meditaurus from this transaction, the resulting gain on bargain purchase was recognized in Additional Paid-In Capital Beverly Asset Purchase In November 2021, the Company entered into an asset purchase agreement to acquire the cannabis license, property lease, and other assets and rights of, and to assume the liabilities and operating obligations associated with, a cannabis dispensary that is currently operating in Beverly, MA. The purchase price is comprised of 2,000,000 shares of the Company’s common stock and $ 5.1 million in cash, with the cash amount to be paid on a monthly basis as a percentage of the business’ monthly gross sales. The purchase is contingent upon the approval of the Massachusetts Cannabis Control Commission, which is expected during the third quarter of 2022 Green Growth Group Inc. In January 2022, the Company entered into a stock purchase agreement to acquire 100 % of the equity ownership of Green Growth Group Inc., an entity that holds a wholesale cannabis license in the state of Illinois, in exchange for 1.9 million 1.5 million 100,000 on the agreement date, Investments In March 2022, the acquisition was approved by the Illinois Department of Agriculture, and in April 2022, the parties consummated the transaction.

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2022
Schedule of Investments [Abstract]
INVESTMENTS	NOTE 4 – INVESTMENTS At March 31, 2022 and December 31, 2021, the Company’s investments were comprised of the following (in thousands): SCHEDULE OF INVESTMENTS March 31, December 31, Current investments: Flowr Corp. (formerly Terrace Inc.) $ 299 $ 251 WM Technology Inc. 954 - Total current investments 1,253 251 Non-current investments: Green Growth Group, Inc. 100 - MembersRSVP LLC - - Total investments $ 1,353 $ 251 Flowr Corp. (formerly Terrace Inc.) In December 2020, Terrace Inc., a Canadian cannabis entity in which the Company had an ownership interest of 8.95 0.4973 This investment is carried at fair value. The increase in fair value of approximately $ 48,000 during the three months ended March 31, 2022, and the decrease in fair value of approximately $ 45,000 during the three months ended March 31, 2021, were reflected in the Gain (Loss) On Change In Fair Value Of Investment Green Growth Group Inc. In January 2022, the Company made a good faith deposit of $ 100,000 in connection with the acquisition of Green Growth Group, Inc. as previously discussed in Note 3 – Acquisitions MembersRSVP LLC In January 2021, the Company and MembersRSVP LLC, an entity that develops cannabis-specific software (“MRSVP”), in which the Company owned a 23.0 11 In addition to the reduction of the Company’s ownership interest to 12.0 In September 2021, MRSVP sold substantially all of its assets pursuant to an asset purchase agreement. As a result of this agreement, the Company received cash proceeds of $ 1,475,000 309,000 As an ongoing member of MRSVP, the Company was entitled to its pro rata share of any additional consideration received by MRSVP pursuant to the asset purchase agreement, which may include securities or other forms of non-cash or in-kind consideration and holdback amounts, if and when it is received and distributed by MRSVP. In February 2022, the Company received 121,968 shares of common stock of WM Technology Inc. (Nasdaq: MAPS), a technology and software infrastructure provider to the cannabis industry, representing the Company’s pro rata share of the additional consideration received by MRSVP pursuant to the asset purchase agreement. The fair value of these shares at March 31, 2022 of approximately $ 954,000 was reflected in current Investments Other Investment Income

DEFERRED RENTS RECEIVABLE

DEFERRED RENTS RECEIVABLE	3 Months Ended
	Mar. 31, 2022
Deferred Rents Receivable
DEFERRED RENTS RECEIVABLE	NOTE 5 – DEFERRED RENTS RECEIVABLE The Company is the lessor under operating leases which contain escalating rents over time, rent holidays, options to renew, requirements to pay property taxes, insurance and/or maintenance costs, and contingent rental payments based on a percentage of monthly tenant revenues. The Company is not the lessor under any finance leases. The Company recognizes fixed rental receipts from such lease agreements on a straight-line basis over the expected lease term. Differences between amounts received and amounts recognized are recorded under Deferred Rents Receivable The Company leases the following owned properties: ● Delaware – a 45,000 expires in 2035 ● Maryland – a 180,000 expires in 2037 ● Massachusetts – a 138,000 expires in October 2022 The Company subleases the following properties: ● Delaware – a 4,000 expiring in April 2027 ● Delaware – a 100,000 square foot warehouse, of which the Company developed 60,000 square feet into a cultivation facility that is subleased to its cannabis-licensed client. The sublease expires in March 2030, with an option to extend the term for three additional five-year periods. The Company intends to develop the remaining space into a processing facility. ● Delaware – a 12,000 The sublease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term At March 31, 2022 and December 31, 2021, cumulative fixed rental receipts under such leases approximated $ 19.9 18.7 21.5 20.4 1.6 1.7 Future minimum rental receipts for non-cancellable leases and subleases as of March 31, 2022 were (in thousands): SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON CANCELABLE LEASE AND SUBLEASE 2022 $ 3,620 2023 4,563 2024 4,626 2025 4,695 2026 3,916 Thereafter 35,830 Total $ 57,250

NOTES RECEIVABLE

NOTES RECEIVABLE	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
NOTES RECEIVABLE	NOTE 6 – NOTES RECEIVABLE At March 31, 2022 and December 31, 2021, notes receivable, including accrued interest, consisted of the following (in thousands): SCHEDULE OF NOTES RECEIVABLES March 31, December 31, First State Compassion Center (initial note) $ 385 $ 403 First State Compassion Center (secondary note) 7,982 7,845 Healer LLC 866 866 High Fidelity Inc. - - Total notes receivable 9,233 9,114 Notes receivable, current portion 129 127 Notes receivable, less current portion $ 9,104 $ 8,987 First State Compassion Center The Company’s cannabis-licensed client in Delaware, First State Compassion Center (“FSCC”), issued a 10 -year promissory note to the Company in May 2016 in the amount of $ 700,000 bearing interest at a rate of 12.5 % per annum, as amended. The monthly payments of approximately $ 10,000 will continue through April 2026, at which time the note will be paid in full. At March 31, 2022 and December 31, 2021, the current portion of this note approximated $ 77,000 and $ 75,000 , respectively, and was included in Notes Receivable, Current Portion In December 2021, financed trade accounts receivable balances from FSCC of approximately $ 7,845,00 in the aggregate were converted into notes receivable whereby FSCC issued promissory notes to the Company in the aggregate amount of approximately $ 7.8 million bearing interest at a rate of 6.0 % per annum. The promissory notes call for the periodic payment of principal and interest throughout the term of the note which matures in December 2025 . At March 31, 2022, the balance of the note included approximately $ 138,000 of unpaid accrued interest. Healer LLC In March 2021, the Company was issued a promissory note in the principal amount of approximately $ 894,000 800,000 94,000 6.0 maturity date in April 2026 Additionally, the Company has the right to offset any licensing fees owed to Healer by the Company in the event Healer fails to make any payment when due. In March 2021, the Company offset approximately $ 28,000 of licensing fees payable to Healer against the principal balance of the revised promissory note, reducing the principal amount to approximately $ 866,000 . At both March 31, 2022 and December 31, 2021, approximately $ 52,000 was current. High Fidelity In August 2021, the Company was fully repaid on a loan to High Fidelity Inc., an entity with cannabis operations in the state of Vermont. The loan had a principal balance of $ 250,000 10.0

INVENTORY

INVENTORY	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
INVENTORY	NOTE 7 – INVENTORY At March 31, 2022 and December 31, 2021, inventory was comprised of the following (in thousands): SCHEDULE OF INVENTORY March 31, December 31, Plants $ 2,413 $ 1,015 Ingredients and other raw materials 494 262 Work-in-process 4,066 4,661 Finished goods 5,265 3,830 Total inventory $ 12,238 $ 9,768

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 8 – PROPERTY AND EQUIPMENT At March 31, 2022 and December 31, 2021, property and equipment consisted of the following (in thousands): SCHEDULE OF PROPERTY AND EQUIPMENT March 31, December 31, Land $ 4,450 $ 4,450 Buildings and building improvements 37,674 35,231 Tenant improvements 16,819 9,745 Furniture and fixtures 1,909 1,888 Machinery and equipment 8,632 7,221 Construction in progress 3,635 10,569 73,119 69,104 Less: accumulated depreciation (7,637 ) (6,954 ) Property and equipment, net $ 65,482 $ 62,150 During the three months ended March 31, 2022 and December 31, 2021, additions to property and equipment approximated $ 4,015,000 3,224,000 The 2022 additions were primarily comprised of (i) the development of facilities in Annapolis, MD and Beverly, MA, and (ii) purchases of building improvements, machinery, and equipment at the facilities in Hagerstown, MD and New Bedford, MA. The 2021 additions consisted primarily of (i) the development of facilities in Annapolis, MD and Milford, DE, and (ii) purchases of building improvements, machinery, and equipment at the Hagerstown, MD facility and both facilities in Massachusetts. The construction in progress balances of approximately $ 3,635,000 10,569,000 Depreciation expense for the three months ended March 31, 2022 and 2021 approximated $ 702,000 462,000

INTANGIBLES

INTANGIBLES	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 9 – INTANGIBLES At March 31, 2022 and December 31, 2021, intangible assets were comprised of (i) the carrying value of cannabis license fees, and (ii) goodwill arising from the Company’s acquisitions. The Company’s cannabis licenses are issued from the states of Illinois and Massachusetts and require the payment of annual fees. These fees, comprised of a fixed component and a variable component based on the level of operations, are capitalized and amortized over the respective twelve-month periods. At March 31, 2022 and December 31, 2021, the carrying value of these cannabis licenses approximated $ 327,000 162,000 The goodwill associated with acquisitions is reviewed on a quarterly basis for impairment. Based on this review and other factors, the goodwill of approximately $ 2,068,000

MORTGAGES

MORTGAGES	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
MORTGAGES	NOTE 10 – MORTGAGES At March 31, 2022 and December 31, 2021, mortgage balances, including accrued interest, were comprised of the following (in thousands): SCHEDULE OF MORTGAGES March 31, December 31, Bank of New England – New Bedford, MA and Middleboro, MA properties $ 12,409 $ 12,499 Bank of New England – Wilmington, DE property 1,434 1,463 DuQuoin State Bank – Anna, IL and Harrisburg, IL properties 770 778 DuQuoin State Bank – Metropolis, IL property 2,607 2,658 South Porte Bank – Mt. Vernon, IL property 820 816 Total mortgages payable 18,040 18,214 Mortgages payable, current portion 1,416 1,400 Mortgages payable, less current portion $ 16,624 $ 16,814 The Company maintains an amended and restated mortgage agreement with the Bank of New England bearing interest at a rate of 6.5 August 2025 4.8 7.2 Promissory Notes 12,409,000 12,499,000 364,000 358,000 The Company has a second mortgage with Bank of New England that is secured by the Company’s property in Wilmington, DE. The mortgage matures in 2031 5.25 1.5 5.25 5.25 1,434,000 1,463,000 122,000 120,000 The Company maintains a mortgage agreement with DuQuoin State Bank (“DSB”) for its purchase of properties in Anna, IL and Harrisburg, IL. On May 5 th 6.75 770,000 778,000 34,000 33,000 In July 2021, the Company purchased the land and building in which it operates its cannabis dispensary in Metropolis, IL. The purchase price consisted of 750,000 705,000 1.6 2.7 6.25 30.0 70.0 2,607,000 2,658,000 76,000 73,000 In February 2020, the Company entered into a mortgage agreement with South Porte Bank for the purchase and development of a property in Mt. Vernon, IL. Pursuant to the amended mortgage agreement, the mortgage shall be repaid in monthly installments of principal and interest of approximately $ 6,000 which began in August 2021 and continues through its maturity in June 2022 , at which time all remaining principal, interest and fees shall be due.

PROMISSORY NOTES

PROMISSORY NOTES	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
PROMISSORY NOTES	NOTE 11 – PROMISSORY NOTES Promissory Note Retirements In March 2021, utilizing a portion of the proceeds from the Hadron transaction discussed in Note 13 – Mezzanine Equity, 15.2 450,000 Promissory Note Conversions During the three months ended March 31, 2021, the noteholder of an $ 8.8 million promissory note issued by the Company in June 2020 converted approximately $ 1.0 million of principal and $ 10,000 of accrued interest into 3,365,972 shares of the Company’s common stock. After such conversion and cash payments of $ 4.6 million in the second half of fiscal 2020, this $ 8.8 million promissory note was amended and restated into a new $ 3.2 million promissory note. During 2021, in a series of transactions, the noteholder converted $ 2.8 8,033,296 400,000 During the three months ended March 31, 2022, the noteholder converted the remaining principal balance of $ 400,000 1,142,858 3.3 Promissory Notes Issued to Purchase Commercial Vehicles In August 2020, the Company entered into a note agreement with First Citizens’ Federal Credit Union for the purchase of a commercial vehicle. The note bears interest at a rate of 5.74 24,000 26,000 5,000 In June 2021, the Company entered into a note agreement with Ally Financial for the purchase of a second commercial vehicle. The note bears interest at the rate of 10.0 31,000 33,000 5,000 Promissory Note Issued by MariMed Hemp Inc. In September 2020, the Company paid down $ 500,000 of principal on a $ 1.0 million promissory note issued in 2019 by MariMed Hemp Inc., the Company’s wholly-owned subsidiary. In March 2021, utilizing a portion of the proceeds from the Hadron transaction discussed in Note 13 – Mezzanine Equity, 200,000 and paid off the remaining principal of $ 500,000 . At March 31, 2022 and December 31, 2021, the Company was carrying an accrued interest balance of approximately $ 125,000 Debt Maturities At March 31, 2022, the aggregate scheduled maturities of the Company’s total debt outstanding were (in thousands): SCHEDULE OF MATURITIES OF OUTSTANDING DEBT 2022 $ 1,267 2023 635 2024 673 2025 720 2026 764 Thereafter 14,037 Total 18,096

DEBENTURES PAYABLE

DEBENTURES PAYABLE	3 Months Ended
	Mar. 31, 2022
Debentures Payable
DEBENTURES PAYABLE	NOTE 12 – DEBENTURES PAYABLE In a series of transactions from the period October 2018 through February 2020, the Company sold an aggregate of $ 21.0 As of March 31, 2021, the holder of the $21M Debentures had converted the entire $ 21.0 million of principal and related accrued interest into the Company’s common stock in a series of conversions, at conversion prices equal to 80.0 % of a calculated average of the daily volume-weighted price preceding the date of conversion. Of these conversions, $ 1.3 million of principal and approximately $ 56,000 of accrued interest were converted into 4,610,645 shares of common stock at a conversion price of $ 0.29 per share during the three months ended March 31, 2021. Additionally, a remaining (i) original issue discount of approximately $ 52,000 , (ii) debt discount of approximately $ 39,000 (such discount having arisen from the issuance of warrants attached to the $21M Debentures), and (iii) beneficial conversion feature of approximately $ 177,000 (such conversion feature having arisen from an in-the-money embedded conversion option on the commitment date), were fully amortized upon the final conversion of the $21M Debentures. All conversions were effected within the terms of the debenture agreements, and accordingly the Company was not required to record a gain or loss on such conversions.

MEZZANINE EQUITY

MEZZANINE EQUITY	3 Months Ended
	Mar. 31, 2022
Mezzanine Equity
MEZZANINE EQUITY	NOTE 13 – MEZZANINE EQUITY Series B Convertible Preferred Stock In 2020, the Company entered into an exchange agreement with two institutional shareholders (the “Exchange Agreement”) whereby the Company (i) issued $ 4.4 Promissory Notes 4,908,333 In connection with the Exchange Agreement, the Company filed (i) a certificate of designation with respect to the rights and preferences of the Series B convertible preferred stock, and (ii) a certificate of elimination to return all shares of the Series A convertible preferred stock, of which no shares were issued or outstanding at the time of filing, to the status of authorized and unissued shares of undesignated preferred stock. The holders of Series B convertible preferred stock (the “Series B Holders”) are entitled to cast the number of votes equal to the number of shares of common stock into which the shares of Series B convertible preferred stock are convertible, together with the holders of common stock as a single class, on most matters. However, the affirmative vote or consent of the Series B Holders voting separately as a class is required for certain acts taken by the Company, including the amendment or repeal of certain charter provisions, liquidation or winding up of the Company, creation of stock senior to the Series B convertible preferred stock, and/or other acts defined in the certificate of designation. The Series B convertible preferred stock shall, with respect to dividend rights and rights on liquidation, winding up and dissolution, rank senior to the Company’s common stock. The Company shall not declare, pay, or set aside any dividends on shares of any other class or series of capital stock of the Company unless the Series B Holders then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series B convertible preferred stock in an amount calculated pursuant to the certificate of designation. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the Series B Holders then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to $ 3.00 At any time on or prior to the six-year anniversary of the issuance date of the Series B convertible preferred stock, (i) the Series B Holders have the option to convert their shares of Series B convertible preferred stock into common stock at a conversion price of $ 3.00 the Company has the option to convert all, but not less than all, shares of Series B convertible preferred stock into common stock at a conversion price of $3.00 if the daily volume weighted average price of common stock (the “VWAP”) exceeds $4.00 per share for at least twenty consecutive trading days prior to the date on which the Company gives notice of such conversion to the Series B Holders On the day following the six-year anniversary of the issuance of the Series B convertible preferred stock, all outstanding shares of Series B convertible preferred stock shall automatically convert into common stock as follows: ● If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share ● If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the quotient of $3.00 per share divided by the sixty-day VWAP, or (ii) pay cash to the Series B Holders equal to $3.00 per share, or (iii) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the sixty-day VWAP per share and pay cash to the Series B Holders at the difference between $3.00 per share and the sixty-day VWAP per share The Company shall at all times when the Series B convertible preferred stock is outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Series B convertible preferred stock, such number of its duly authorized shares of common stock as shall from time to time be sufficient to effect the conversion of all outstanding Series B convertible preferred stock. Series C Convertible Preferred Stock In March 2021, the Company entered into a securities purchase agreement with Hadron Healthcare Master Fund (“Hadron”) with respect to a financing facility of up to $ 46.0 At the closing of the transaction in March 2021, Hadron purchased $ 23.0 3.70 four 6,216,216 15,540,540 1.087 9.5 387,000 In connection with the closing of the transaction, the Company filed a certificate of designation with respect to the rights and preferences of the Series C convertible preferred stock. Such stock is zero coupon, non-voting. and has a liquidation preference equal to its investment amount plus declared but unpaid dividends. Holders of Series C convertible preferred stock are entitled to receive dividends on an as-converted basis. Of the $ 23.0 7.3 15.7 Promissory Notes The balance of the facility was designated to fund future acquisitions, including the Kind acquisition, on the same aforementioned terms as the initial proceeds. Notwithstanding, Hadron did not fund the cash portion of the Kind purchase price, and the Company is currently in negotiations with Hadron to amend and extend the facility to be utilized for future expansion opportunities. There is no assurance that any extension will be implemented. The transaction imposes certain covenants on the Company with respect to the incurrence of new indebtedness, the issuance of additional shares of any designation of preferred stock, and the payment of distributions.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 14 – STOCKHOLDERS’ EQUITY Stockholder Resolutions At the Company’s 2021 annual meeting of stockholders in September 2021 (the “Annual Meeting”), stockholders approved an amendment to the Company’s certificate of incorporation increasing the number of authorized shares of common stock from 500 700 million . Also at the Annual Meeting, stockholders approved an amendment to the Company’s Amended and Restated 2018 Stock Award and Incentive Plan (the “Plan”) increasing the aggregate number shares reserved for issuance under the Plan from 40 million to 70 million . Undesignated Preferred Stock In February 2020, the Company filed a certificate of elimination to return all shares of formerly designated Series A convertible preferred stock to the status of authorized and unissued shares of undesignated preferred stock. Common Stock During the three months ended March 31, 2022 and 2021, the Company granted 2,717 6,877 2,000 5,000 Common Stock Subscribed But Not Issued In March 2022, the Company issued 375,000 274,000 42,857 30,000 1,000 Loss On Obligations Settled with Equity During the three months ended March 31, 2021, the Company issued 11,413 5,000 As previously disclosed in Note 11 – Promissory Notes 1,142,858 400,000 3,365,972 1,010,000 As previously disclosed in Note 12 – Debentures Payable 4,610,645 1.3 56,000 As further disclosed in Note 15 – Options 10,000 No As further disclosed in Note 16 – Warrants 50,000 No Common Stock Issuance Obligations At March 31, 2022 and 2021, the Company was obligated to issue 2,717 6,877 2,000 5,000

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 15 – STOCK OPTIONS During the three months ended March 31, 2021, the Company granted five 1,262,000 0.51 0.90 541,000 170,000 Compensation expense in the first quarter of 2022 and 2021 for options issued in previous periods, and continuing to be amortized over their respective vesting periods, approximated $ 2,469,000 124,000 During the three months ended March 31, 2022, options to purchase 10,000 0.30 During the three months ended March 31, 2021, options to purchase 50,000 No Stock options outstanding and exercisable as of March 31, 2022 were: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Shares Under Option Remaining Life per Share Outstanding Exercisable in Years $0.140 80,000 80,000 3.28 $0.149 500,000 500,000 3.76 $0.169 200,000 200,000 3.62 $0.225 2,000,000 1,625,000 3.61 $0.250 50,000 50,000 2.92 $0.250 20,000 20,000 3.17 $0.250 50,000 25,000 3.57 $0.250 800,000 800,000 3.62 $0.250 80,000 80,000 3.65 $0.300 388,000 388,000 3.00 $0.417 900,000 900,000 2.74 $0.505 100,000 100,000 3.76 $0.505 800,000 400,000 3.78 $0.590 15,000 15,000 2.69 $0.690 15,000 - 4.68 $0.693 500,000 - 4.69 $0.700 650,000 50,000 4.67 $0.740 520,000 425,625 4.08 $0.755 1,050,000 550,000 4.73 $0.770 200,000 200,000 0.75 $0.800 25,000 - 4.64 $0.830 287,000 287,000 3.98 $0.830 600,000 150,000 4.16 $0.840 878,921 878,921 4.29 $0.840 99,000 59,400 4.34 $0.850 90,000 49,375 4.21 $0.850 72,500 14,375 4.63 $0.870 250,000 - 4.76 $0.880 11,550,000 5,925,000 4.28 $0.880 15,000 7,500 4.37 $0.880 410,000 102,500 4.59 $0.890 10,000 5,000 3.81 $0.892 40,000 30,000 3.81 $0.895 25,000 25,000 3.82 $0.898 11,250,000 5,625,000 4.50 $0.900 50,000 50,000 1.11 $0.910 50,000 50,000 0.56 $0.920 300,000 37,500 4.27 $0.928 500,000 200,000 4.36 $0.950 50,000 50,000 0.75 $0.970 100,000 100,000 4.21 $0.983 145,000 61,250 4.24 $0.990 500,000 125,000 4.47 $0.992 300,000 300,000 2.49 $1.000 15,000 15,000 2.21 $1.000 125,000 125,000 2.59 $1.350 100,000 100,000 1.33 $1.950 375,000 375,000 1.25 $2.320 100,000 100,000 1.45 $2.450 2,000,000 2,000,000 0.73 $2.500 100,000 100,000 1.41 $2.650 200,000 200,000 1.48 $2.850 56,250 56,250 0.70 $2.850 100,000 100,000 1.70 $3.000 25,000 25,000 1.71 $3.725 100,000 100,000 1.69 39,811,671 23,837,696

WARRANTS

WARRANTS	3 Months Ended
	Mar. 31, 2022
Warrants
WARRANTS	NOTE 16 – WARRANTS During the three months ended March 31, 2021, the Company issued four-year warrants to Hadron to purchase up to 15,540,540 1.087 Mezzanine Equity 23.0 9.5 2,100,000 0.50 0.83 1,487,000 During the three months ended March 31, 2021, warrants to purchase 50,000 0.15 No During the three months ended March 31, 2021, warrants to purchase 225,000 0.90 1.15 No At March 31, 2022 and 2021, warrants to purchase up to 26,351,571 32,282,708 0.25 5.50

REVENUES

REVENUES	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
REVENUES	NOTE 17 – REVENUES For the three months ended March 31, 2022 and 2021, the Company’s revenues were comprised of the following major categories (in thousands): SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES Three Months Ended March 31, 2022 2021 Product sales - retail $ 21,441 $ 15,224 Product sales - wholesale 6,062 5,725 Real estate rentals 1,587 1,809 Supply procurement 1,190 520 Management fees 753 896 Licensing fees 249 469 Total revenues $ 31,282 $ 24,643 For the three months ended March 31, 2022 and 2021, revenues from two clients represented 12 14

BAD DEBTS

BAD DEBTS	3 Months Ended
	Mar. 31, 2022
Bad Debts
BAD DEBTS	NOTE 18 – BAD DEBTS The Company maintains two types of reserves to address uncertain collections of amounts due—an allowance against trade accounts receivable (the “AR Allowance”), and a reserve against cash advanced by the Company to its cannabis-licensed clients for working capital purposes (the WC Reserve”). During the three months ended March 31, 2022, the Company made no change to the AR Allowance, and increased the WC Reserve by approximately $ 14,000 850,000 175,000 1,025,000 Bad Debts

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 19 – RELATED PARTY TRANSACTIONS In July 2021, the Company granted five-year options to purchase up to 100,000 shares of common stock to each of the Company’s three independent board members at an exercise price of $ 0.88 per share. In December 2021, the CEO and CFO each exercised options to purchase 100,000 shares of common stock on a cashless basis. The exercise price of $ 0.63 per share was paid via the surrender by each individual of 73,256 shares of common stock. The Company’s corporate offices are leased from an entity in which the Company’s CFO has an investment interest. This lease expires in October 2028 and contains a five-year extension option. During the three months ended March 31, 2022 and 2021, expenses incurred under this lease approximated $ 39,000 The Company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the Company’s COO. The aggregate purchases from this entity during the three months ended March 31, 2022 and 2021 approximated $ 872,000 825,000 The Company pays royalties on the revenue generated from its Betty’s Eddies product line to an entity owned by the Company’s COO and its SVP of Sales under a royalty agreement. This agreement was amended effective January 1, 2021 whereby, among other modifications, the royalty percentage changed from 2.5% on all sales of Betty’s Eddies products to (i) 3.0% and 10.0% of wholesale sales of existing products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively, and (ii) 0.5% and 1.0% of wholesale sales of future developed products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively 56,000 83,000 During the three months ended March 31, 2022 and 2021, one of the Company’s majority-owned subsidiaries paid aggregate distributions of approximately $ 11,000 and $ 9,000 , respectively, to the Company’s CEO and CFO, who own minority equity interests in such subsidiary. During the three months ended March 31, 2022, another of the Company’s majority owned subsidiaries paid distributions of approximately $ 3,000 to a current employee who owns a minority equity interest in such subsidiary. During the three months ended March 31, 2022 and 2021, the Company purchased fixed assets and consulting services of approximately $ 392,000 265,000 During the three months ended March 31, 2022 and 2021, the Company purchased fixed assets of approximately $ 82,000 310,000 The Company’s mortgages with Bank of New England, DuQuoin State Bank, and South Porte Bank are personally guaranteed by the Company’s CEO and CFO.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 20 – COMMITMENTS AND CONTINGENCIES Lease Commitments The Company is the lessee under six operating leases and four finance leases The details of the Company’s operating lease agreements are as follows: ● Delaware – 4,000 five-year lease that expires in April 2027 that the Company has developed into a cannabis dispensary which is subleased to its cannabis-licensed client ● Delaware – a 100,000 square foot warehouse, of which the Company developed 60,000 square feet into a cultivation facility that is being subleased to its cannabis-licensed client. The lease expires in March 2030, with an option to extend the term for three additional five-year periods . ● Delaware – a 12,000 lease expires in January 2026 ● Nevada – 10,000 expiring in 2024 ● Massachusetts – 10,000 expiring in 2028 option to extend the term for an additional five-year period ● Maryland – a 2,700 expires in July 2022 The Company leases machinery and office equipment under finance leases that expire in February 2024 through February 2026 The components of lease expense for the three months ended March 31, 2022 were as follows (in thousands): SCHEDULE OF COMPONENTS OF LEASE EXPENSE Operating lease cost $ 277 Finance lease cost: Amortization of right-of-use assets $ 19 Interest on lease liabilities 7 Total finance lease cost $ 26 The weighted average remaining lease term for operating leases is 7.1 3.8 7.5 12.0 Future minimum lease payments as of March 31, 2022 under all non-cancelable leases having an initial or remaining term of more than one year were (in thousands): SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON CANCELABLE OPERATING LEASES Operating Leases Finance Leases 2022 $ 849 $ 135 2023 1,119 173 2024 1,050 153 2025 1,025 150 2026 970 21 Thereafter 2,611 - Total lease payments 7,624 $ 632 Less: imputed interest (2,153 ) (82 ) $ 5,471 $ 550 In November 2021, the Company entered into lease agreements for six retail properties, each with square footage between 4,000 6,000 31.00 . In the event the Company is awarded one or more of the six Ohio cannabis licenses for which it had previously applied, the Company can extend the term of one or more of the Ohio Leases to ten years (with two additional five-year options to extend) upon the payment of $ 50,000 In February 2022, the Company was notified that it was awarded a cannabis dispensary license from the state of Ohio. The Company is awaiting the final verification process to be completed by the state. As of March 31, 2022, the lease terms of the Ohio Leases were all less than one year, and accordingly the Company was not required to record a right-of-use asset and corresponding lease liability on its balance sheet. In April 2022, the Company extended the term of one of the Ohio Leases, and the remaining five Ohio Leases were terminated. Terminated Employment Agreement An employment agreement which commenced in 2012 with Thomas Kidrin, the former CEO of the Company, was terminated by the Company in 2017 1,043,000 In July 2019, Mr. Kidrin, also a former director of the Company, filed a complaint in the Massachusetts Superior Court, which alleged the Company failed to pay all wages owed to him and breached the employment agreement, and requested multiple damages, attorney fees, costs, and interest. The Company moved to dismiss certain counts of the complaint and asserted counterclaims against Mr. Kidrin alleging breach of contract, breach of fiduciary duty, money had and received, and unjust enrichment. In August 2021, the parties entered into a settlement agreement and general release pursuant to which (i) Mr. Kidrin’s complaint was dismissed with prejudice, (ii) the Company issued to Mr. Kidrin five-year warrants to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $ 0.50 per share, (iii) the Company irrevocably transferred intangible assets relating to the online virtual worlds business the Company had conducted in early 2014, prior to its pivot into the legal cannabis industry (such assets had zero carrying value on the Company’s balance sheet), and (iv) each party released and discharged the other from all claims, losses, and liabilities. In August 2021, the fair value of the warrants of approximately $ 776,000 1,043,000 Maryland Litigation Following the consummation of the Kind acquisition previously discussed in Note 3 – Acquisitions DiPietro Lawsuit In April 2022, the parties agreed to dismiss all direct claims and counterclaims asserted in this litigation, as set forth below. In addition to their direct claims, the parties also asserted derivative claims, which may be dismissed only with the court’s approval. On April 12, 2022, the court approved the form of notice to be delivered to unit holders of Mia Development LLC (“Mia”) and Mari Holdings MD LLC (“Mari-MD”), majority-owned subsidiaries of the Company, and scheduled a hearing to approve dismissal of all derivative claims for June 8, 2022. In this action, Jennifer DiPietro, one of the former members of Kind, directly and derivatively on behalf of Mari-MD and Mia, commenced a suit in August 2020 against the Company’s CEO, CFO, and wholly-owned subsidiary MariMed Advisors Inc. (“MMA”), in Suffolk Superior Court, Massachusetts. DiPietro brought claims for breach of fiduciary duty, breach of contract, fraud in the inducement, aiding and abetting the alleged breach of fiduciary duty, and also sought access to books and records and an accounting related to her investments in Mari-MD and Mia. DiPietro sought unspecified money damages and rescission of her interest in Mari-MD, but not of her investment in Mia, which had provided substantial returns to her as a member. The Company answered the complaint and MMA filed counterclaims against DiPietro on its own behalf and derivatively on behalf of Mari-MD for breach of her fiduciary duties to each of those entities, and for tortious interference with Mari-MD’s lease and MMA’s management services agreement with Kind. In December 2021, the parties entered into a global confidential settlement and release agreement, along with the parties to the aforementioned Maryland litigation. As of the same date, MMA and Jennifer DiPietro entered into a membership interest purchase agreement pursuant to which the Company will purchase DiPietro’s interests in Mia and Mari-MD, as previously discussed in Note 3 – Acquisitions Bankruptcy Claim During 2019, the Company’s MMH subsidiary sold and delivered hemp seed inventory to GenCanna Global Inc., a Kentucky-based cultivator, producer, and distributor of hemp (“GenCanna”). At the time of sale, the Company owned a 33.5 29.0 In February 2020, GenCanna USA, GenCanna’s wholly-owned operating subsidiary, under pressure from certain of its creditors including MGG Investment Group LP, GenCanna’s senior lender (“MGG”), agreed to convert a previously-filed involuntary bankruptcy proceeding with the U.S. Bankruptcy Court in the Eastern District of Kentucky (the “Bankruptcy Court”) into a voluntary Chapter 11 proceeding. In addition, GenCanna and GenCanna USA’s subsidiary, Hemp Kentucky LLC (collectively with GenCanna and GenCanna USA, the “GenCanna Debtors”), filed voluntary petitions under Chapter 11 in the Bankruptcy Court. In May 2020, after an abbreviated solicitation/bid/sale process, the Bankruptcy Court, over numerous objections by creditors and shareholders of the GenCanna Debtors which included the Company, entered an order authorizing the sale of all or substantially all of the assets of the GenCanna Debtors to MGG. After the consummation of the sale of all or substantially all of their assets and business, the GenCanna Debtors n/k/a OGGUSA, Inc. and OGG, Inc. (the “OGGUSA Debtors”) filed their liquidating plan of reorganization (the “Liquidating Plan”) to collect various prepetition payments and commercial claims against third parties, liquidate the remaining assets of the ODDUSA Debtors, and make payments to creditors. The Company and the unsecured creditors committee filed objections to such Liquidating Plan, including opposition to the release of litigation against the OGGUSA Debtors’ senior lender, MGG, for lender liability, equitable subordination, and return of preference. As a part of such plan confirmation process, the OGGUSA Debtors filed various objections to proofs of claims filed by various creditors, including the proof of claim in the amount of approximately $ 33.6 31.0 Since the approval of the Liquidating Plan, the OGGUSA Debtors have been in the process of liquidating the remaining assets, negotiating and prosecuting objections to other creditors’ claims, and pursuing the collection of accounts receivable and Chapter 5 bankruptcy avoidance claims. In January 2022, the Company, at the request of the Liquidating Plan administrator for the OGGUSA Debtors, executed a written release of claims, if any, of the Company against Huron Consulting Group (“Huron”), a financial consulting and management company retained by the senior lender of the OGGUSA Debtors to perform loan management services for the lender and OGGUSA Debtors prior to and during their Chapter 11 bankruptcy cases. Such release was executed in connection with a comprehensive settlement agreement between the OGGUSA Debtors and Huron. In consideration for the Company’s execution of the release, Huron paid an additional $ 40,000 As of the date of this filing, there is still insufficient information as to what portion, if any, of the Company’s allowed claim will be paid upon the completion of the liquidation of the remaining assets of the OGGUSA Debtors.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 21 – SUBSEQUENT EVENTS Consummation of Kind Acquisition and Dismissal of Litigation In April 2022, the Maryland Medical Cannabis Commission approved the Company’s acquisition of Kind as previously discussed in Note 3 – Acquisitions 13.5 In April 2022, the Company and DiPietro agreed to dismiss all direct claims and counterclaims asserted in a separate litigation between them, as previously discussed in Note 20 – Commitments and Contingencies Consummation of Green Growth Group Acquisition In April 2022, the acquisition of Green Growth Group previously discussed in Note 3 – Acquisitions Lease Agreements In April 2022, the Company extended the term of one of the Ohio Leases previously discussed in Note 20 – Commitments and Contingencies Equity Transactions In April 2022, warrants to purchase 750,000 0.50 515,039 234,961

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In accordance with GAAP, interim financial statements are not required to contain all of the disclosures normally required in annual financial statements. In addition, the results of operations of interim periods may not necessarily be indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s most recent audited annual financial statements and accompanying notes for the year ended December 31, 2021. Certain reclassifications may have been made to prior periods’ presentation to conform to the current period presentation. These reclassifications had no effect on previously reported income or cash flows.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at March 31, 2022: SCHEDULE OF MAJORITY OWNED SUBSIDIARIES Subsidiary: Percentage MariMed Advisors Inc. 100.0% Mia Development LLC 89.5% Mari Holdings IL LLC 100.0% Mari Holdings MD LLC 97.4% Mari Holdings NJ LLC 100.0% Mari Holdings NV LLC 100.0% Mari Holdings Metropolis LLC 70.0% Mari Holdings Mt. Vernon LLC 100.0% Mari Mfg LLC 100.0% Hartwell Realty Holdings LLC 100.0% iRollie LLC 100.0% ARL Healthcare Inc. 100.0% KPG of Anna LLC 100.0% KPG of Harrisburg LLC 100.0% MariMed OH LLC 100.0% MariMed Hemp Inc. 100.0% Meditaurus LLC 100.0% Intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values. At both March 31, 2022 and December 31, 2021, cash of approximately $ 5,101,000 was held in escrow, primarily comprised of a $ 5,000,000 escrow deposit in connection with the acquisition of Kind Therapeutics USA LLC as further discussed in Note 3 – Acquisitions The Company’s cash and cash equivalents are maintained with recognized financial institutions located in the United States. In the normal course of business, the Company may carry balances with certain financial institutions that exceed federally insured limits. The Company has not experienced losses on balances in excess of such limits and management believes the Company is not exposed to significant risks in that regard.
Accounts Receivable	Accounts Receivable Accounts receivable consist of trade receivables and are carried at their estimated collectible amounts. The Company provides credit to its clients in the form of payment terms. The Company limits its credit risk by performing credit evaluations of its clients and maintaining a reserve, if deemed necessary, for potential credit losses. Such evaluations include the review of a client’s outstanding balances with consideration towards such client’s historical collection experience, as well as prevailing economic and market conditions and other factors. Based on such evaluations, the Company maintained a reserve of approximately $ 41.4 million at both March 31, 2022 and December 31, 2021. For further discussion on receivable reserves, please refer to Note 18 – Bad Debts Bankruptcy Claim – Commitments and Contingencies.
Inventory	Inventory Inventory is carried at the lower of cost or net realizable value, with the cost being determined on a first-in, first-out (FIFO) basis. The Company allocates a certain percentage of overhead cost to its manufactured inventory; such allocation is based on square footage and other industry-standard criteria. The Company reviews physical inventory for obsolescence and/or excess and will record a reserve if necessary. As of the date of this report, no reserve was deemed necessary.
Investments	Investments Investments are comprised of equity holdings in public and private companies. These investments are recorded at fair value on the Company’s consolidated balance sheet, with changes to fair value included in income. Investments are evaluated for permanent impairment and are written down if such impairments are deemed to have occurred.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 606, Revenue from Contract with Customers, ● Identify the contract(s) with a customer; ● Identify the performance obligations in the contract(s); ● Determine the transaction price; ● Allocate the transaction price to the performance obligations in the contract(s); and ● Recognize revenue as the performance obligation is satisfied. Additionally, when another party is involved in providing goods or services to the Company’s clients, a determination is made as to who—the Company or the other party—is acting in the capacity as the principal in the sale transaction, and who is the agent arranging for goods or services to be provided by the other party. The Company is typically considered the principal if it controls the specified good or service before such good or service is transferred to its client. The Company may also be deemed to be the principal even if it engages another party (an agent) to satisfy some of the performance obligations on its behalf, provided the Company (i) takes on certain responsibilities, obligations, and risks, (ii) possesses certain abilities and discretion, or (iii) other relevant indicators of the sale. If deemed an agent, the Company would not recognize revenue for the performance obligations it does not satisfy. The Company’s main sources of revenue are comprised of the following: ● Product Sales – direct sales of cannabis and cannabis-infused products primarily by the Company’s retail dispensaries and wholesale operations in Massachusetts and Illinois. This revenue is recognized when products are delivered or at retail points-of-sale. ● Real Estate – rental income and additional rental fees generated from leasing of the Company’s state-of-the-art, regulatory-compliant cannabis facilities to its cannabis-licensed clients. Rental income is generally a fixed amount per month that escalates over the respective lease terms, while additional rental fees are based on a percentage of tenant revenues that exceed specified amounts. ● Management – fees for providing the Company’s cannabis clients with comprehensive oversight of their cannabis cultivation, production, and dispensary operations. These fees are based on a percentage of such clients’ revenue and are recognized after services have been performed. ● Supply Procurement – resale of cultivation and production resources, supplies, and equipment, acquired by the Company from top national vendors at volume discounted prices, to its clients and third-parties within the cannabis industry. The Company recognizes this revenue after the delivery and acceptance of goods by the purchaser. ● Licensing – revenue from the sale of Company’s branded products including Betty’s Eddies and Kalm Fusion, and from the sublicensing of contracted brands including Healer and Tikun Olam, to regulated dispensaries throughout the United States and Puerto Rico. The recognition of this revenue occurs when the products are delivered.
Research and Development Costs	Research and Development Costs Research and development costs are charged to operations as incurred.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred. The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, forty years; tenant improvements, the remaining duration of the related lease ; furniture and fixtures, seven to ten years; and machinery and equipment, ten years. Land is not depreciated. The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the undiscounted future cash flows of such asset over the anticipated holding period. An impairment loss is measured by the excess of the asset’s carrying amount over its estimated fair value. Impairment analyses are based on management’s current plans, asset holding periods, and currently available market information. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements. In the three months ended March 31, 2022 and 2021, based on the results of management’s impairment analyses, there were no impairment losses.
Leases	Leases The consolidated financial statements reflect the Company’s adoption of ASC 842, Leases Right-of-use assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term, utilizing the Company’s incremental borrowing rate. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates the recoverability of its fixed assets and other assets in accordance with ASC 360-10-15, Impairment or Disposal of Long-Lived Assets
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows the provisions of ASC 820, Fair Value Measurement Financial Instruments, Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data. The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable, approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined using the Black-Scholes pricing model and employing several inputs such as the expected life of instrument, the exercise price, the expected risk-free interest rate, the expected dividend yield, the value of the Company’s common stock on issuance date, and the expected volatility of such common stock. The following table summarizes the range of inputs used by the Company during the three months ended March 31, 2022 and 2021: SCHEDULE OF ASSUMPTIONS USED Three Months Ended 2022 2021 Life of instrument * 3.0 5.0 Volatility factors * 1.230 1.266 Risk-free interest rates * 0.36 0.85 Dividend yield * 0 * No options or warrants were issued by the Company during the three months ended March 31, 2022. The expected life of an instrument is calculated using the simplified method pursuant to Staff Accounting Bulletin Topic 14, Share-Based Payment The Company amortizes the fair value of option and warrant issuances on a straight-line basis over the requisite service period of each instrument.
Extinguishment of Liabilities	Extinguishment of Liabilities The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation,
Income Taxes	Income Taxes The Company uses the asset and liability method to account for income taxes in accordance with ASC 740, Income Taxes ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no Certain of the Company’s subsidiaries are subject to the provisions of Section 280E of the Internal Revenue Code, as amended, which prohibits businesses from deducting certain expenses associated with the trafficking of controlled substances within the meaning of Schedule I and II of the Controlled Substances Act. Such non-deductibility of certain ordinary business expenses results in permanent differences and can cause the Company’s effective tax rate to be highly variable and not necessarily correlated with pre-tax income.
Related Party Transactions	Related Party Transactions The Company follows ASC 850, Related Party Disclosures In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.
Comprehensive Income	Comprehensive Income The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income
Earnings Per Share	Earnings Per Share Earnings per common share is computed pursuant to ASC 260, Earnings Per Share At March 31, 2022 and 2021, there were potentially dilutive securities convertible into shares of common stock comprised of (i) stock options – convertible into 39,811,671 11,017,750 26,351,571 32,282,708 4,908,333 31,081,080 zero 10,705,513 For the three months ended March 31, 2022 and 2021, the aforementioned potentially dilutive securities increased the number of weighted average common shares outstanding on a diluted basis by 44,127,540 35,613,671
Commitments and Contingencies	Commitments and Contingencies The Company follows ASC 450, Contingencies If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.
Beneficial Conversion Features on Convertible Debt	Beneficial Conversion Features on Convertible Debt Convertible instruments that are not bifurcated as a derivative pursuant to ASC 815, Derivatives and Hedging A beneficial conversion feature is a nondetachable conversion feature that is “in-the-money” at the commitment date. The in-the-money portion, also known as the intrinsic value, is recorded in equity, with an offsetting discount to the carrying amount of convertible debt to which it is attached. The discount is amortized to interest expense over the life of the debt with adjustments to amortization upon full or partial conversions of the debt.
Risk and Uncertainties	Risk and Uncertainties The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.
Off Balance Sheet Arrangements	Off Balance Sheet Arrangements The Company does not have any off-balance sheet arrangements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF MAJORITY OWNED SUBSIDIARIES	The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and the following majority-owned subsidiaries at March 31, 2022: SCHEDULE OF MAJORITY OWNED SUBSIDIARIES Subsidiary: Percentage MariMed Advisors Inc. 100.0% Mia Development LLC 89.5% Mari Holdings IL LLC 100.0% Mari Holdings MD LLC 97.4% Mari Holdings NJ LLC 100.0% Mari Holdings NV LLC 100.0% Mari Holdings Metropolis LLC 70.0% Mari Holdings Mt. Vernon LLC 100.0% Mari Mfg LLC 100.0% Hartwell Realty Holdings LLC 100.0% iRollie LLC 100.0% ARL Healthcare Inc. 100.0% KPG of Anna LLC 100.0% KPG of Harrisburg LLC 100.0% MariMed OH LLC 100.0% MariMed Hemp Inc. 100.0% Meditaurus LLC 100.0%
SCHEDULE OF ASSUMPTIONS USED	SCHEDULE OF ASSUMPTIONS USED Three Months Ended 2022 2021 Life of instrument * 3.0 5.0 Volatility factors * 1.230 1.266 Risk-free interest rates * 0.36 0.85 Dividend yield * 0 * No options or warrants were issued by the Company during the three months ended March 31, 2022.

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2022
Schedule of Investments [Abstract]
SCHEDULE OF INVESTMENTS	At March 31, 2022 and December 31, 2021, the Company’s investments were comprised of the following (in thousands): SCHEDULE OF INVESTMENTS March 31, December 31, Current investments: Flowr Corp. (formerly Terrace Inc.) $ 299 $ 251 WM Technology Inc. 954 - Total current investments 1,253 251 Non-current investments: Green Growth Group, Inc. 100 - MembersRSVP LLC - - Total investments $ 1,353 $ 251

DEFERRED RENTS RECEIVABLE (Tabl

DEFERRED RENTS RECEIVABLE (Tables)	3 Months Ended
	Mar. 31, 2022
Deferred Rents Receivable
SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON CANCELABLE LEASE AND SUBLEASE	Future minimum rental receipts for non-cancellable leases and subleases as of March 31, 2022 were (in thousands): SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON CANCELABLE LEASE AND SUBLEASE 2022 $ 3,620 2023 4,563 2024 4,626 2025 4,695 2026 3,916 Thereafter 35,830 Total $ 57,250

NOTES RECEIVABLE (Tables)

NOTES RECEIVABLE (Tables)	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
SCHEDULE OF NOTES RECEIVABLES	At March 31, 2022 and December 31, 2021, notes receivable, including accrued interest, consisted of the following (in thousands): SCHEDULE OF NOTES RECEIVABLES March 31, December 31, First State Compassion Center (initial note) $ 385 $ 403 First State Compassion Center (secondary note) 7,982 7,845 Healer LLC 866 866 High Fidelity Inc. - - Total notes receivable 9,233 9,114 Notes receivable, current portion 129 127 Notes receivable, less current portion $ 9,104 $ 8,987

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	At March 31, 2022 and December 31, 2021, inventory was comprised of the following (in thousands): SCHEDULE OF INVENTORY March 31, December 31, Plants $ 2,413 $ 1,015 Ingredients and other raw materials 494 262 Work-in-process 4,066 4,661 Finished goods 5,265 3,830 Total inventory $ 12,238 $ 9,768

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	At March 31, 2022 and December 31, 2021, property and equipment consisted of the following (in thousands): SCHEDULE OF PROPERTY AND EQUIPMENT March 31, December 31, Land $ 4,450 $ 4,450 Buildings and building improvements 37,674 35,231 Tenant improvements 16,819 9,745 Furniture and fixtures 1,909 1,888 Machinery and equipment 8,632 7,221 Construction in progress 3,635 10,569 73,119 69,104 Less: accumulated depreciation (7,637 ) (6,954 ) Property and equipment, net $ 65,482 $ 62,150

MORTGAGES (Tables)

MORTGAGES (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
SCHEDULE OF MORTGAGES	At March 31, 2022 and December 31, 2021, mortgage balances, including accrued interest, were comprised of the following (in thousands): SCHEDULE OF MORTGAGES March 31, December 31, Bank of New England – New Bedford, MA and Middleboro, MA properties $ 12,409 $ 12,499 Bank of New England – Wilmington, DE property 1,434 1,463 DuQuoin State Bank – Anna, IL and Harrisburg, IL properties 770 778 DuQuoin State Bank – Metropolis, IL property 2,607 2,658 South Porte Bank – Mt. Vernon, IL property 820 816 Total mortgages payable 18,040 18,214 Mortgages payable, current portion 1,416 1,400 Mortgages payable, less current portion $ 16,624 $ 16,814

PROMISSORY NOTES (Tables)

PROMISSORY NOTES (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
SCHEDULE OF MATURITIES OF OUTSTANDING DEBT	At March 31, 2022, the aggregate scheduled maturities of the Company’s total debt outstanding were (in thousands): SCHEDULE OF MATURITIES OF OUTSTANDING DEBT 2022 $ 1,267 2023 635 2024 673 2025 720 2026 764 Thereafter 14,037 Total 18,096

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE	Stock options outstanding and exercisable as of March 31, 2022 were: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Shares Under Option Remaining Life per Share Outstanding Exercisable in Years $0.140 80,000 80,000 3.28 $0.149 500,000 500,000 3.76 $0.169 200,000 200,000 3.62 $0.225 2,000,000 1,625,000 3.61 $0.250 50,000 50,000 2.92 $0.250 20,000 20,000 3.17 $0.250 50,000 25,000 3.57 $0.250 800,000 800,000 3.62 $0.250 80,000 80,000 3.65 $0.300 388,000 388,000 3.00 $0.417 900,000 900,000 2.74 $0.505 100,000 100,000 3.76 $0.505 800,000 400,000 3.78 $0.590 15,000 15,000 2.69 $0.690 15,000 - 4.68 $0.693 500,000 - 4.69 $0.700 650,000 50,000 4.67 $0.740 520,000 425,625 4.08 $0.755 1,050,000 550,000 4.73 $0.770 200,000 200,000 0.75 $0.800 25,000 - 4.64 $0.830 287,000 287,000 3.98 $0.830 600,000 150,000 4.16 $0.840 878,921 878,921 4.29 $0.840 99,000 59,400 4.34 $0.850 90,000 49,375 4.21 $0.850 72,500 14,375 4.63 $0.870 250,000 - 4.76 $0.880 11,550,000 5,925,000 4.28 $0.880 15,000 7,500 4.37 $0.880 410,000 102,500 4.59 $0.890 10,000 5,000 3.81 $0.892 40,000 30,000 3.81 $0.895 25,000 25,000 3.82 $0.898 11,250,000 5,625,000 4.50 $0.900 50,000 50,000 1.11 $0.910 50,000 50,000 0.56 $0.920 300,000 37,500 4.27 $0.928 500,000 200,000 4.36 $0.950 50,000 50,000 0.75 $0.970 100,000 100,000 4.21 $0.983 145,000 61,250 4.24 $0.990 500,000 125,000 4.47 $0.992 300,000 300,000 2.49 $1.000 15,000 15,000 2.21 $1.000 125,000 125,000 2.59 $1.350 100,000 100,000 1.33 $1.950 375,000 375,000 1.25 $2.320 100,000 100,000 1.45 $2.450 2,000,000 2,000,000 0.73 $2.500 100,000 100,000 1.41 $2.650 200,000 200,000 1.48 $2.850 56,250 56,250 0.70 $2.850 100,000 100,000 1.70 $3.000 25,000 25,000 1.71 $3.725 100,000 100,000 1.69 39,811,671 23,837,696

REVENUES (Tables)

REVENUES (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES	For the three months ended March 31, 2022 and 2021, the Company’s revenues were comprised of the following major categories (in thousands): SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES Three Months Ended March 31, 2022 2021 Product sales - retail $ 21,441 $ 15,224 Product sales - wholesale 6,062 5,725 Real estate rentals 1,587 1,809 Supply procurement 1,190 520 Management fees 753 896 Licensing fees 249 469 Total revenues $ 31,282 $ 24,643

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF LEASE EXPENSE	The components of lease expense for the three months ended March 31, 2022 were as follows (in thousands): SCHEDULE OF COMPONENTS OF LEASE EXPENSE Operating lease cost $ 277 Finance lease cost: Amortization of right-of-use assets $ 19 Interest on lease liabilities 7 Total finance lease cost $ 26
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON CANCELABLE OPERATING LEASES	Future minimum lease payments as of March 31, 2022 under all non-cancelable leases having an initial or remaining term of more than one year were (in thousands): SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON CANCELABLE OPERATING LEASES Operating Leases Finance Leases 2022 $ 849 $ 135 2023 1,119 173 2024 1,050 153 2025 1,025 150 2026 970 21 Thereafter 2,611 - Total lease payments 7,624 $ 632 Less: imputed interest (2,153 ) (82 ) $ 5,471 $ 550

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)	Mar. 31, 2022ft²
Real Estate [Abstract]
Area of land	300,000

SCHEDULE OF MAJORITY OWNED SUBS

SCHEDULE OF MAJORITY OWNED SUBSIDIARIES (Details)	Mar. 31, 2022
MariMed Advisors Inc. [Member]
Percentage Owned	100.00%
Mia Development LLC [Member]
Percentage Owned	89.50%
Mari Holdings IL LLC [Member]
Percentage Owned	100.00%
Mari Holdings MD LLC [Member]
Percentage Owned	97.40%
Mari Holdings NJ LLC [Member]
Percentage Owned	100.00%
Mari Holdings NV LLC [Member]
Percentage Owned	100.00%
Mari Holdings Metropolis LLC [Member]
Percentage Owned	70.00%
Mari Holdings Mt. Vernon LLC [Member]
Percentage Owned	100.00%
Mari Mfg LLC [Member]
Percentage Owned	100.00%
Hartwell Realty Holdings LLC [Member]
Percentage Owned	100.00%
iRollie LLC [Member]
Percentage Owned	100.00%
ARL Healthcare Inc. [Member]
Percentage Owned	100.00%
KPG of Anna LLC [Member]
Percentage Owned	100.00%
KPG of Harrisburg LLC [Member]
Percentage Owned	100.00%
MariMed OH LLC [Member]
Percentage Owned	100.00%
MariMed Hemp Inc. [Member]
Percentage Owned	100.00%
Meditaurus LLC [Member]
Percentage Owned	100.00%

SCHEDULE OF ASSUMPTIONS USED (D

SCHEDULE OF ASSUMPTIONS USED (Details)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Volatility factors, minimum	1.23%
Volatility factors, maximum	1.266%
Risk-free interest rates, minimum	0.36%
Risk-free interest rates, maximum	0.85%
Dividend yield	0.00%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Life of instrument	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Life of instrument	5 years

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Restricted cash and investments			$ 5,101,000
Asset impairment charges	$ 0	$ 0
Unrecognized Tax Benefits	$ 0	$ 0
Share-Based Payment Arrangement, Option [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	39,811,671	11,017,750
Warrant [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	26,351,571	32,282,708
Series B Preferred Stocks [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	4,908,333	4,908,333
Series C Preferred Stocks [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	31,081,080	31,081,080
Promissory Notes [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	0	10,705,513
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Antidilutive securities	44,127,540	35,613,671
Building and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	forty
Tenant Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	the remaining duration of the related lease
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	seven
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	ten
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful lives	ten
Accounts Receivable [Member]
Property, Plant and Equipment [Line Items]
Bad debt reserve for tax purposes of qualified lender	$ 41,400,000		$ 41,400,000
Kind Therapeutics USA Inc. [Member]
Property, Plant and Equipment [Line Items]
Escrow deposit	$ 5,000,000

ACQUISITIONS (Details Narrative

ACQUISITIONS (Details Narrative) - USD ($)	Apr. 13, 2022	Jan. 31, 2022	Nov. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2019	Jun. 30, 2022	Mar. 31, 2022
Business Acquisition [Line Items]
Common stock value,issued					$ 334,000			$ 336,000
Beverly asset purchase [Member]
Business Acquisition [Line Items]
Stock issued during period shares purchase of assets			2,000,000
Stock issued during period value purchase of assets			$ 5,100,000
Mari Holdings MD LLC [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent							99.70%
Mia Development LLC [Member]
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent							94.30%
Mari-MD & Mia [Member]
Business Acquisition [Line Items]
Asset Acquisition, Price of Acquisition, Expected	$ 2,000,000
Kind Therapeutics USA LLC. [Member]
Business Acquisition [Line Items]
Ownership percentage					100.00%
Payments to Acquire Management Contract Rights					$ 13,500,000
Escrow Deposit Disbursements Related to Property Acquisition					5,000,000
Kind Therapeutics USA LLC. [Member] | 6% Promissory notes [Member]
Business Acquisition [Line Items]
Line of Credit Facility, Current Borrowing Capacity					$ 6,500,000
The Harvest Foundation LLC [Member]
Business Acquisition [Line Items]
Percentage of voting interests acquired						100.00%
Number of Shares Issued in Transaction						1,000,000
Sale of stock, value						$ 1,200,000
Warrants to purchase shares						400,000
Meditaurus LLC [Member]
Business Acquisition [Line Items]
Ownership percentage				30.00%		70.00%
Number of Shares Issued in Transaction				100,000
Common stock value,issued				$ 94,000
Cash acquired from acquisition				10,000
Net of cash acquired						$ 2,800,000
Noncontrolling interest increase from business combination				$ 975,000
Green Growth Group Inc Member]
Business Acquisition [Line Items]
Ownership percentage		100.00%
Payments to Acquire Management Contract Rights		$ 1,900,000
Common stock value,issued		1,500,000
Business combination contingent consideration liability		$ 100,000

SCHEDULE OF INVESTMENTS (Detail

SCHEDULE OF INVESTMENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule of Investments [Line Items]
Current investments	$ 1,253	$ 251
Non-current investments	100
Total investments	1,353	251
Green Growth Group Inc Member]
Schedule of Investments [Line Items]
Non-current investments	100
MembersRSVP LLC [Member]
Schedule of Investments [Line Items]
Non-current investments
Flowr Corp. (Formerly Terrace Inc.) [Member]
Schedule of Investments [Line Items]
Current investments	299	251
WM Technology Inc [Member]
Schedule of Investments [Line Items]
Current investments	$ 954

INVESTMENTS (Details Narrative)

INVESTMENTS (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended
	Feb. 28, 2022	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Jan. 31, 2022
Restructuring Cost and Reserve [Line Items]
Gain (Loss) on Investments					$ 48,000	$ (45,000)
MembersRSVP LLC [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage by parent			12.00%
Membership interest transferred			11.00%
Proceeds from investment		$ 1,475,000
Gain loss on sale of investment		$ 309,000
Stock Issued During Period, Shares, Purchase of Assets	121,968
Investment Owned, at Fair Value					954,000
MembersRSVP LLC [Member] | Membership Interest Agreement [Member]
Restructuring Cost and Reserve [Line Items]
Ownership percentage by parent			23.00%
Flowr Corp. (Formerly Terrace Inc.) [Member]
Restructuring Cost and Reserve [Line Items]
Percentage for acquired interest rate				8.95%
Number of shares received under acquisition				0.4973
Gain (Loss) on Investments					$ 48,000	$ 45,000
Green Growth Group Inc Member]
Restructuring Cost and Reserve [Line Items]
Business combination contingent consideration liability							$ 100,000

SCHEDULE OF FUTURE MINIMUM RENT

SCHEDULE OF FUTURE MINIMUM RENTAL RECEIPTS FOR NON CANCELABLE LEASE AND SUBLEASE (Details) $ in Thousands	Mar. 31, 2022USD ($)
Deferred Rents Receivable
2022	$ 3,620
2023	4,563
2024	4,626
2025	4,695
2026	3,916
Thereafter	35,830
Total	$ 57,250

DEFERRED RENTS RECEIVABLE (Deta

DEFERRED RENTS RECEIVABLE (Details Narrative) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)ft²	Dec. 31, 2021USD ($)
Area of land	300,000
Operating lease income | $	$ 19.9	$ 18.7
Revenue recognization | $	21.5	20.4
Deferred rents receivable | $	$ 1.6	$ 1.7
DELAWARE
Area of land	45,000
Lease expiration description	expires in 2035
DELAWARE | Cannabis Dispensary [Member]
Area of land	4,000
Lease expiration description	expiring in April 2027
DELAWARE | Warehouse [Member]
Area of land	100,000
DELAWARE | Cultivation and Processing Facility [Member]
Area of land	60,000
Lease expiration description	The sublease expires in March 2030, with an option to extend the term for three additional five-year periods.
DELAWARE | Cannabis Production Facility [Member]
Area of land	12,000
Lease expiration description	The sublease expires in January 2026 and contains an option to negotiate an extension at the end of the lease term
MARYLAND
Area of land	180,000
Lease expiration description	expires in 2037
MASSACHUSETTS
Area of land	138,000
Lease expiration description	expires in October 2022

SCHEDULE OF NOTES RECEIVABLES (

SCHEDULE OF NOTES RECEIVABLES (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Total notes receivable	$ 9,233	$ 9,114
Notes receivable, current portion	129	127
Notes receivable, less current portion	9,104	8,987
First State Compassion Center (initial note) [Member]
Total notes receivable	385	403
First State Compassion Center (secondary note) [Member]
Total notes receivable	7,982	7,845
Healer LLC [Member]
Total notes receivable	866	866
High Fidelity Inc [Member]
Total notes receivable

NOTES RECEIVABLE (Details Narra

NOTES RECEIVABLE (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2021	May 31, 2016	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Aug. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Proceeds from sale of notes receivable			$ 43,000	$ 69,000
Notes receivable related parties current			129,000		$ 127,000
Convertible note payable			9,233,000		$ 9,114,000
First State Compassion Center (“FSCC”) [Member] | Convertible Promissory Note [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest rate					6.00%
Convertible note payable					$ 7,845
Convertible note payable					$ 7,800,000
Debt instrument maturity date description					The promissory notes call for the periodic payment of principal and interest throughout the term of the note which matures in December 2025
Interest receivable					$ 138,000
First State Compassion Center (“FSCC”) [Member]
Defined Benefit Plan Disclosure [Line Items]
Debt instrument term		10 years
Proceeds from sale of notes receivable		$ 700,000
Interest rate		12.50%
Debt instrument periodic payment		$ 10,000
Notes receivable related parties current			77,000		75,000
Healer LLC [Member]
Defined Benefit Plan Disclosure [Line Items]
Proceeds from sale of notes receivable	$ 894,000
Interest rate	6.00%			6.00%
Notes receivable related parties current			$ 52,000		$ 52,000
Convertible note payable	$ 866,000			$ 866,000
Debt instrument maturity date description	maturity date in April 2026
Interest receivable	$ 94,000			94,000
Debt instrument face amount	800,000			$ 800,000
Licensing fees	$ 28,000
High Fidelity Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest rate						10.00%
Debt instrument face amount						$ 250,000

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Plants	$ 2,413	$ 1,015
Ingredients and other raw materials	494	262
Work-in-process	4,066	4,661
Finished goods	5,265	3,830
Total inventory	$ 12,238	$ 9,768

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 73,119	$ 69,104
Less: accumulated depreciation	(7,637)	(6,954)
Property and equipment, net	65,482	62,150
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	4,450	4,450
Buildings and Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	37,674	35,231
Tenant Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	16,819	9,745
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,909	1,888
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	8,632	7,221
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,635	$ 10,569

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Additions to property and equipment	$ 4,015,000		$ 3,224,000
Depreciation expense	702,000	$ 462,000
Milford, DE and Annapolis, MD [Member]
Construction in progress	$ 3,635,000		$ 10,569,000

INTANGIBLES (Details Narrative)

INTANGIBLES (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Indefinite-Lived Intangible Assets [Line Items]
Goodwill	$ 2,068,000	$ 2,068,000
Cannabis Licenses [Member]
Indefinite-Lived Intangible Assets [Line Items]
License carrying value	$ 327,000	$ 162,000

SCHEDULE OF MORTGAGES (Details)

SCHEDULE OF MORTGAGES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Total mortgages payable	$ 18,096,000
Mortgage [Member]
Short-Term Debt [Line Items]
Total mortgages payable	18,040	$ 18,214
Mortgages payable, current portion	1,416	1,400
Mortgages payable, less current portion	16,624	16,814
Mortgage [Member] | Bank of New England - New Bedford, MA and Middleboro, MA properties [Member]
Short-Term Debt [Line Items]
Total mortgages payable	12,409	12,499
Mortgage [Member] | Bank of New England - Wilmington, DE property [Member]
Short-Term Debt [Line Items]
Total mortgages payable	1,434	1,463
Mortgage [Member] | DuQuoin State Bank - Anna, IL and Harrisburg, IL properties [Member]
Short-Term Debt [Line Items]
Total mortgages payable	770	778
Mortgage [Member] | DuQuoin State Bank - Metropolis, IL property [Member]
Short-Term Debt [Line Items]
Total mortgages payable	2,607	2,658
Mortgage [Member] | South Porte Bank - Mt. Vernon, IL property [Member]
Short-Term Debt [Line Items]
Total mortgages payable	$ 820	$ 816

MORTGAGES (Details Narrative)

MORTGAGES (Details Narrative) - USD ($)	May 31, 2021	Sep. 30, 2021	Jul. 31, 2021	Feb. 29, 2020	Mar. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Debt instrument, face amount					$ 18,096,000
Mortgage Agreement [Member] | DuQuoin State Bank [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	6.75%
Debt instrument, face amount					770,000	$ 778,000
Debt principal amount, current					$ 34,000	33,000
Mortgage Agreement [Member] | South Porte Bank [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity				June 2022
Debt instrument periodic payment				$ 6,000
New Bedford, Massachusetts [Member] | Mortgage Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period					6.50%
Debt instrument, maturity					August 2025
Proceeds from notes payable					$ 4,800,000
New Bedford and Middleboro [Member] | Mortgage Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount					12,409,000	12,499,000
Debt principal amount, current					364,000	358,000
New Bedford and Middleboro [Member] | Mortgage Agreement [Member] | Promissory Note [Member]
Short-Term Debt [Line Items]
Proceeds from notes payable					7,200,000
DELAWARE | Mortgage Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period		5.25%
Debt instrument, maturity		2031
Debt instrument, face amount					1,434,000	1,463,000
Debt principal amount, current					122,000	120,000
DELAWARE | Mortgage Agreement [Member] | Prime Rate [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period		1.50%
DELAWARE | Mortgage Agreement [Member] | Floor Rate [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period		5.25%
Metropolis [Member] | Mortgage Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount			$ 1,600,000		2,607,000	2,658,000
Debt principal amount, current					$ 76,000	$ 73,000
Stock issued during period, shares, purchase of assets			750,000
Stock issued during period, shares, purchase of assets			$ 705,000
Metropolis [Member] | Second Mortgage Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount			$ 2,700,000
Debt instrument, basis spread on variable rate			6.25%
Percentage Owned			70.00%
Metropolis [Member] | Second Mortgage Agreement [Member] | Mari Holdings Metropolics LLC [Member]
Short-Term Debt [Line Items]
Percentage Owned			30.00%

SCHEDULE OF MATURITIES OF OUTST

SCHEDULE OF MATURITIES OF OUTSTANDING DEBT (Details) $ in Thousands	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
2022	$ 1,267
2023	635
2024	673
2025	720
2026	764
Thereafter	14,037
Total	$ 18,096

PROMISSORY NOTES (Details Narra

PROMISSORY NOTES (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Aug. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021
Short-Term Debt [Line Items]
Repayments of notes payable					$ 2,000	$ 15,801,000
Notes payable, current					10,000			$ 10,000
MariMed Hemp Inc. [Member]
Short-Term Debt [Line Items]
Debt instrument face amount			$ 1,000,000
Repayments of notes payable		$ 500,000	$ 500,000
Interest expense debt		200,000
Interest payable					125,000			125,000
Note Agreement [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period	10.00%
Notes Payable					31,000			33,000
Notes payable, current					5,000			5,000
Mezzanine Equity [Member]
Short-Term Debt [Line Items]
Debt instrument face amount		15,200,000				15,200,000
Debt instrument, unamortized discount		450,000				450,000
$8.8 million Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount		8,800,000				8,800,000		400,000
Debt instrument, converted principal amount					$ 400,000	1,000,000		$ 2,800,000
Debt conversion original debt amount						$ 10,000
Debt instrument converted, shares issued					1,142,858	3,365,972		8,033,296
Repayments of notes payable							$ 4,600,000
$8.8 million Amended Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount		$ 3,200,000				$ 3,200,000
$3.3 Million Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount					$ 3,300,000
Promissory Notes [Member] | First Citizens Federal Credit Union [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period				5.74%
Notes Payable					24,000			$ 26,000
Notes payable, current					$ 5,000			$ 5,000

DEBENTURES PAYABLE (Details Nar

DEBENTURES PAYABLE (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Feb. 29, 2020
Short-Term Debt [Line Items]
Amortization of debt discount premium		$ 52,000
21M Convertible Debentures [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount		1,300,000	$ 21,000,000
Debt instrument, unamortized discount		52,000
Amortization of debt discount premium		39,000
Debt instrument, convertible, beneficial conversion feature		177,000
21M Convertible Debentures [Member] | Holder [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount		$ 21,000,000
Debt conversion converted instrument rate		80.00%
Interest payable		$ 56,000
Debt instrument converted, shares issued		4,610,645
Debt instrument convertible conversion price		$ 0.29

MEZZANINE EQUITY (Details Narra

MEZZANINE EQUITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
Stock issued during period, shares, new issues			11,413
Stock issued during period, value, new issues			$ 5,000
Payments of stock issuance costs			$ 387,000
Proceeds from issuance or sale of equity	$ 23,000,000
Payments for construction in process	$ 7,300,000
Common Stock [Member]
Stock issued during period, shares, new issues		375,000
Stock issued during period, value, new issues		$ 274,000
Class of warrant or right, number of securities called by warrants or rights	32,282,708	26,351,571	32,282,708
Maximum [Member] | Common Stock [Member]
Warrant exercise price		$ 5.50
Hadron Healthcare Master Fund [Member] | Warrant [Member]
Warrant exercise price	$ 1.087		$ 1.087
Fair value adjustment of warrants	$ 9,500,000
Payments of stock issuance costs	$ 387,000
Hadron Healthcare Master Fund [Member] | Maximum [Member] | Common Stock [Member]
Class of warrant or right, number of securities called by warrants or rights	15,540,540		15,540,540
3M Note [Member]
Repayments of debt and lease obligation	$ 15,700,000
Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member] | Warrant [Member]
Warrants term	4 years		4 years
Series B Convertible Preferred Stock [Member]
Shares issued, price per share		3
Preferred stock, convertible conversion price		$ 3
Preferred stock conversion, description		the Company has the option to convert all, but not less than all, shares of Series B convertible preferred stock into common stock at a conversion price of $3.00 if the daily volume weighted average price of common stock (the “VWAP”) exceeds $4.00 per share for at least twenty consecutive trading days prior to the date on which the Company gives notice of such conversion to the Series B Holders
Series B Convertible Preferred Stock [Member] | Volume Weighted Average Price Less Than Or Equal To $0.50 Per Share [Member]
Preferred stock conversion, description		If the sixty-day VWAP is less than or equal to $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price of $1.00 per share, and pay cash to the Series B Holders equal to the difference between the 60-day VWAP and $3.00 per share, or (ii) pay cash to the Series B Holders equal to $3.00 per share
Series B Convertible Preferred Stock [Member] | Volume Weighted Average Price Greater Than $0.50 Per Share [Member]
Preferred stock conversion, description		If the sixty-day VWAP is greater than $0.50 per share, the Company shall have the option to (i) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the quotient of $3.00 per share divided by the sixty-day VWAP, or (ii) pay cash to the Series B Holders equal to $3.00 per share, or (iii) convert all shares of Series B convertible preferred stock into common stock at a conversion price per share equal to the sixty-day VWAP per share and pay cash to the Series B Holders at the difference between $3.00 per share and the sixty-day VWAP per share
Series B Convertible Preferred Stock [Member] | Exchange Agreement [Member] | Two Institutional Shareholders [Member]
Debt instrument, face amount				$ 4,400,000
Conversion of stock, shares converted				4,908,333
Series C Convertible Preferred Stock [Member] | Hadron Healthcare Master Fund [Member] | Warrant [Member]
Stock issued during period, shares, new issues	6,216,216
Series C Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member]
Shares issued, price per share	$ 3.70		$ 3.70
Stock issued during period, value, new issues	$ 23,000,000
Series C Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Hadron Healthcare Master Fund [Member] | Maximum [Member]
Stock issued during period, shares, new issues	46,000,000

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock shares authorized		700,000,000		700,000,000	500,000,000
Number of shares granted		2,717	6,877
Number of stock options granted, value		$ 2,000	$ 5,000
Stock issued during period, shares			11,413
Stock issued during period, value			$ 5,000
Common Stock Issuance Obligations [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares granted		2,717	6,877
Number of stock options granted, value		$ 2,000	$ 5,000
Options Held [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares options exercised		10,000	0
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrant issued to purchase shares		0	50,000
2022 Promissory Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt instrument converted, shares issued		1,142,858
Debt conversion, shares issued, amount		$ 400,000
2021 Promissory Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt instrument converted, shares issued		3,365,972
Debt conversion, shares issued, amount		$ 1,010,000
$21M Debentures Holder [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt instrument converted, shares issued			4,610,645
Debt conversion, shares issued, amount			$ 1,300,000
Accrued interest			$ 56,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, shares		375,000
Stock issued during period, value		$ 274,000
Common stock issued to settle obligations, shares	42,857
Common stock issued to settle obligations	$ 30,000
Loss on obligations settled with equity		$ 1,000
Number of shares options exercised		10,000
Amended and Restated 2018 Stock Award and Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, capital shares reserved for future issuance		70,000,000			40,000,000

SCHEDULE OF STOCK OPTIONS OUTST

SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Shares under option, Outstanding	39,811,671
Shares under option, Exercisable	23,837,696
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.140
Shares under option, Outstanding	80,000
Shares under option, Exercisable	80,000
Remaining Life in Years	3 years 3 months 10 days
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.149
Shares under option, Outstanding	500,000
Shares under option, Exercisable	500,000
Remaining Life in Years	3 years 9 months 3 days
Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.169
Shares under option, Outstanding	200,000
Shares under option, Exercisable	200,000
Remaining Life in Years	3 years 7 months 13 days
Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.225
Shares under option, Outstanding	2,000,000
Shares under option, Exercisable	1,625,000
Remaining Life in Years	3 years 7 months 9 days
Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Shares under option, Outstanding	50,000
Shares under option, Exercisable	50,000
Remaining Life in Years	2 years 11 months 1 day
Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Shares under option, Outstanding	20,000
Shares under option, Exercisable	20,000
Remaining Life in Years	3 years 2 months 1 day
Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Shares under option, Outstanding	50,000
Shares under option, Exercisable	25,000
Remaining Life in Years	3 years 6 months 25 days
Range Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Shares under option, Outstanding	800,000
Shares under option, Exercisable	800,000
Remaining Life in Years	3 years 7 months 13 days
Range Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.250
Shares under option, Outstanding	80,000
Shares under option, Exercisable	80,000
Remaining Life in Years	3 years 7 months 24 days
Range Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.300
Shares under option, Outstanding	388,000
Shares under option, Exercisable	388,000
Remaining Life in Years	3 years
Range Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.417
Shares under option, Outstanding	900,000
Shares under option, Exercisable	900,000
Remaining Life in Years	2 years 8 months 26 days
Range Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.505
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	3 years 9 months 3 days
Range Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.505
Shares under option, Outstanding	800,000
Shares under option, Exercisable	400,000
Remaining Life in Years	3 years 9 months 10 days
Range Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.590
Shares under option, Outstanding	15,000
Shares under option, Exercisable	15,000
Remaining Life in Years	2 years 8 months 8 days
Range Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.690
Shares under option, Outstanding	15,000
Shares under option, Exercisable
Remaining Life in Years	4 years 8 months 4 days
Range Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.693
Shares under option, Outstanding	500,000
Shares under option, Exercisable
Remaining Life in Years	4 years 8 months 8 days
Range Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.700
Shares under option, Outstanding	650,000
Shares under option, Exercisable	50,000
Remaining Life in Years	4 years 8 months 1 day
Range Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.740
Shares under option, Outstanding	520,000
Shares under option, Exercisable	425,625
Remaining Life in Years	4 years 29 days
Range Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.755
Shares under option, Outstanding	1,050,000
Shares under option, Exercisable	550,000
Remaining Life in Years	4 years 8 months 23 days
Range Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.770
Shares under option, Outstanding	200,000
Shares under option, Exercisable	200,000
Remaining Life in Years	9 months
Range Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.800
Shares under option, Outstanding	25,000
Shares under option, Exercisable
Remaining Life in Years	4 years 7 months 20 days
Range Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.830
Shares under option, Outstanding	287,000
Shares under option, Exercisable	287,000
Remaining Life in Years	3 years 11 months 23 days
Range Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.830
Shares under option, Outstanding	600,000
Shares under option, Exercisable	150,000
Remaining Life in Years	4 years 1 month 28 days
Range Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.840
Shares under option, Outstanding	878,921
Shares under option, Exercisable	878,921
Remaining Life in Years	4 years 3 months 14 days
Range Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.840
Shares under option, Outstanding	99,000
Shares under option, Exercisable	59,400
Remaining Life in Years	4 years 4 months 2 days
Range Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.850
Shares under option, Outstanding	90,000
Shares under option, Exercisable	49,375
Remaining Life in Years	4 years 2 months 15 days
Range Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.850
Shares under option, Outstanding	72,500
Shares under option, Exercisable	14,375
Remaining Life in Years	4 years 7 months 17 days
Range Twenty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.870
Shares under option, Outstanding	250,000
Shares under option, Exercisable
Remaining Life in Years	4 years 9 months 3 days
Range Twenty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.880
Shares under option, Outstanding	11,550,000
Shares under option, Exercisable	5,925,000
Remaining Life in Years	4 years 3 months 10 days
Range Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.880
Shares under option, Outstanding	15,000
Shares under option, Exercisable	7,500
Remaining Life in Years	4 years 4 months 13 days
Range Thirty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.880
Shares under option, Outstanding	410,000
Shares under option, Exercisable	102,500
Remaining Life in Years	4 years 7 months 2 days
Range Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.890
Shares under option, Outstanding	10,000
Shares under option, Exercisable	5,000
Remaining Life in Years	3 years 9 months 21 days
Range Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.892
Shares under option, Outstanding	40,000
Shares under option, Exercisable	30,000
Remaining Life in Years	3 years 9 months 21 days
Range Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.895
Shares under option, Outstanding	25,000
Shares under option, Exercisable	25,000
Remaining Life in Years	3 years 9 months 25 days
Range Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.898
Shares under option, Outstanding	11,250,000
Shares under option, Exercisable	5,625,000
Remaining Life in Years	4 years 6 months
Range Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.900
Shares under option, Outstanding	50,000
Shares under option, Exercisable	50,000
Remaining Life in Years	1 year 1 month 9 days
Range Thirty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.910
Shares under option, Outstanding	50,000
Shares under option, Exercisable	50,000
Remaining Life in Years	6 months 21 days
Range Thirty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.920
Shares under option, Outstanding	300,000
Shares under option, Exercisable	37,500
Remaining Life in Years	4 years 3 months 7 days
Range Thirty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.928
Shares under option, Outstanding	500,000
Shares under option, Exercisable	200,000
Remaining Life in Years	4 years 4 months 9 days
Range Fourty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.950
Shares under option, Outstanding	50,000
Shares under option, Exercisable	50,000
Remaining Life in Years	9 months
Range Fourty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.970
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	4 years 2 months 15 days
Range Fourty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.983
Shares under option, Outstanding	145,000
Shares under option, Exercisable	61,250
Remaining Life in Years	4 years 2 months 26 days
Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.990
Shares under option, Outstanding	500,000
Shares under option, Exercisable	125,000
Remaining Life in Years	4 years 5 months 19 days
Range Fourty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 0.992
Shares under option, Outstanding	300,000
Shares under option, Exercisable	300,000
Remaining Life in Years	2 years 5 months 26 days
Range Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1
Shares under option, Outstanding	15,000
Shares under option, Exercisable	15,000
Remaining Life in Years	2 years 2 months 15 days
Range Fourty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1
Shares under option, Outstanding	125,000
Shares under option, Exercisable	125,000
Remaining Life in Years	2 years 7 months 2 days
Range Fourty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1.350
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	1 year 3 months 29 days
Range Fourty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 1.950
Range Fourty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Shares under option, Outstanding	375,000
Shares under option, Exercisable	375,000
Remaining Life in Years	1 year 3 months
Range Fourty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.320
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	1 year 5 months 12 days
Range Fifty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.450
Shares under option, Outstanding	2,000,000
Shares under option, Exercisable	2,000,000
Remaining Life in Years	8 months 23 days
Range Fifty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.500
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	1 year 4 months 28 days
Range Fifty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.650
Shares under option, Outstanding	200,000
Shares under option, Exercisable	200,000
Remaining Life in Years	1 year 5 months 23 days
Range Fifty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.850
Shares under option, Outstanding	56,250
Shares under option, Exercisable	56,250
Remaining Life in Years	8 months 12 days
Range Fifty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 2.850
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	1 year 8 months 12 days
Range Fifty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 3
Shares under option, Outstanding	25,000
Shares under option, Exercisable	25,000
Remaining Life in Years	1 year 8 months 15 days
Range Fifty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding and exercisable exercise price per share | $ / shares	$ 3.725
Shares under option, Outstanding	100,000
Shares under option, Exercisable	100,000
Remaining Life in Years	1 year 8 months 8 days

STOCK OPTIONS (Details Narrativ

STOCK OPTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payment award, options, grants in period, gross	2,717	6,877
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average remaining contractual term		5 years
Fair value of options granted		$ 541,000
Amortized fair value of options granted		170,000
Share-based payment arrangement, expense	$ 2,469,000	$ 124,000
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payment award, options, grants in period, gross		1,262,000
Grants in period, weighted average exercise price		$ 0.90
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grants in period, weighted average exercise price		$ 0.51
Employee Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based payment award, options, exercises in period	10,000
Share-based compensation arrangements by share-based payment award, options, exercise, weighted average exercise price	$ 0.30
Share-based compensation arrangement by share-based payment award, options, expiration	0	50,000

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Warrant Exercised [Member]
Warrants to purchase shares		50,000
Warrant exercise price		$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised	0
Warrants expired	0
Warrant Expired [Member]
Warrants to purchase shares		225,000
Common Stock [Member]
Warrants to purchase shares	26,351,571	32,282,708
Minimum [Member] | Warrant Exercised [Member]
Warrant exercise price		$ 1.15
Minimum [Member] | Common Stock [Member]
Warrant exercise price	$ 0.25
Maximum [Member] | Warrant Exercised [Member]
Warrant exercise price		$ 0.90
Maximum [Member] | Common Stock [Member]
Warrant exercise price	$ 5.50
Warrant 1 [Member]
Warrants to purchase shares		15,540,540
Warrant exercise price		$ 1.087
Proceeds from issuance of warrants		$ 23,000,000
Fair value of warrants		$ 9,500,000
Warrant 2 [Member]
Warrants to purchase shares		2,100,000
Fair value of warrants		$ 1,487,000
Warrant 2 [Member] | Minimum [Member]
Warrant exercise price		$ 0.50
Warrant 2 [Member] | Maximum [Member]
Warrant exercise price		$ 0.83

SCHEDULE OF REVENUES COMPRISED

SCHEDULE OF REVENUES COMPRISED OF MAJOR CATEGORIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenues	$ 31,282	$ 24,643
Product Sales - Retail [Member]
Disaggregation of Revenue [Line Items]
Total revenues	21,441	15,224
Product Sales - Wholesale [Member]
Disaggregation of Revenue [Line Items]
Total revenues	6,062	5,725
Real Estate [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,587	1,809
Supply Procurement [Member]
Disaggregation of Revenue [Line Items]
Total revenues	1,190	520
Management Service [Member]
Disaggregation of Revenue [Line Items]
Total revenues	753	896
License and Service [Member]
Disaggregation of Revenue [Line Items]
Total revenues	$ 249	$ 469

REVENUES (Details Narrative)

REVENUES (Details Narrative)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | Two Clients [Member]
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	12.00%	14.00%

BAD DEBTS (Details Narrative)

BAD DEBTS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Bad debts	$ 14,000	$ 1,025,000
AR Allowance [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Accounts receivable allowance for credit loss	$ 14,000	850,000
Increase in working capital		$ 175,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Dec. 31, 2021	Jul. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Operating lease, expense			$ 39,000	$ 39,000
Payments to acquire property, plant, and equipment			4,015,000	2,308,000
Payments to acquire fixed assets and consulting services			$ 392,000	265,000
Royalty Agreement [Member] | Bettys Eddies Products [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Royalty percentage description			(i) 3.0% and 10.0% of wholesale sales of existing products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively, and (ii) 0.5% and 1.0% of wholesale sales of future developed products within the product line if sold directly by the Company, or licensed by the Company for sale by third-parties, respectively
Accrued royalties			$ 56,000	83,000
Three Independent Board Members [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Options grant period		5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award		100,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.88
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.63
Chief Executive Officer [Member] | Cashless [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	100,000
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Surrender Of Common Stock	73,256
Chief Operating Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Payments to acquire property, plant, and equipment			872,000	825,000
CEO and CFO [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Payments to acquire additional interest in subsidiaries			11,000	9,000
Current Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Payments to acquire additional interest in subsidiaries			3,000
Employee [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Payments to acquire property, plant, and equipment			$ 82,000	$ 310,000

SCHEDULE OF COMPONENTS OF LEASE

SCHEDULE OF COMPONENTS OF LEASE EXPENSE (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 277
Amortization of right-of-use assets	19
Interest on lease liabilities	7
Total finance lease cost	$ 26

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER ALL NON CANCELABLE OPERATING LEASES (Details) $ in Thousands	Mar. 31, 2022USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
Operating Leases, 2022	$ 849
Operating Leases, 2023	1,119
Operating Leases, 2024	1,050
Operating Leases, 2025	1,025
Operating Leases, 2026	970
Operating Leases, Thereafter	2,611
Operating Lease, Total lease payments	7,624
Less: Operating Leases, Imputed Interest	(2,153)
Operating Leases Liability	5,471
Finance Lease, Liability, to be Paid [Abstract]
Finance Lease, 2022	135
Finance Lease, 2023	173
Finance Lease, 2024	153
Finance Lease, 2025	150
Finance Lease, 2026	21
Finance Lease, Thereafter
Finance Lease, Total lease payments	632
Less: Finance Lease, imputed interest	(82)
Finance Lease Liability	$ 550

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Aug. 31, 2021USD ($)$ / shares	Jan. 31, 2022USD ($)	Nov. 30, 2021USD ($)ft²	May 31, 2020USD ($)	Mar. 31, 2022USD ($)ft²	Dec. 31, 2021USD ($)	Dec. 31, 2019USD ($)
Product Liability Contingency [Line Items]
Lessee, operating lease, description			In November 2021, the Company entered into lease agreements for six retail properties, each with square footage between 4,000 and 6,000 square feet, in the state of Ohio (each an “Ohio Lease” and collectively the “Ohio Leases”). Each Ohio Lease has an initial lease period of eleven months, with a minimum rent of $31.00 per square foot which increases 3.0% annually		The Company is the lessee under six operating leases and four finance leases
Area of land					300,000
Operating lease, weighted average remaining lease term					7 years 1 month 6 days
Finance lease, weighted average remaining lease term					3 years 9 months 18 days
Lease cost | $			$ 31
Lessor, operating lease, option to extend					In the event the Company is awarded one or more of the six Ohio cannabis licenses for which it had previously applied, the Company can extend the term of one or more of the Ohio Leases to ten years (with two additional five-year options to extend) upon the payment of $50,000 for each extended Ohio Lease, and develop the premises of such extended lease(s) into a cannabis dispensary.
Accrued liabilities, current | $					$ 1,728,000	$ 1,349,000
OGGUSA Debtors [Member]
Product Liability Contingency [Line Items]
Bankruptcy claim filed | $		$ 40,000		$ 33,600,000
Bankruptcy claim by court | $				$ 31,000,000
GenCanna Global Inc. [Member]
Product Liability Contingency [Line Items]
Percentage Owned							33.50%
Related party receivable | $							$ 29,000,000
Extended Ohio Lease Agreement [Member]
Product Liability Contingency [Line Items]
Lease cost | $					$ 50,000
Terminated Employment Agreement [Member]
Product Liability Contingency [Line Items]
Agreement term description					An employment agreement which commenced in 2012 with Thomas Kidrin, the former CEO of the Company, was terminated by the Company in 2017
Accrued liabilities, current | $	$ 1,043,000				$ 1,043,000
Warrants and Rights Outstanding | $	$ 1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.50
Fair value warrants | $	$ 776,000
Minimum [Member]
Product Liability Contingency [Line Items]
Area of land			4,000
Operating lease, weighted average discount rate, percent					7.50%
Maximum [Member]
Product Liability Contingency [Line Items]
Area of land			6,000
Operating lease, weighted average discount rate, percent					12.00%
Finance Lease Commitments [Member] | Machinery and Office Equipment [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					expire in February 2024 through February 2026
DELAWARE
Product Liability Contingency [Line Items]
Area of land					45,000
DELAWARE | Premises [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					lease expires in January 2026
DELAWARE | Retails Space [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					five-year lease that expires in April 2027 that the Company has developed into a cannabis dispensary which is subleased to its cannabis-licensed client
Area of land					4,000
DELAWARE | Warehouse [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					The lease expires in March 2030, with an option to extend the term for three additional five-year periods
Area of land					100,000
DELAWARE | Cultivation and Processing Facility [Member]
Product Liability Contingency [Line Items]
Area of land					60,000
DELAWARE | Premises [Member]
Product Liability Contingency [Line Items]
Area of land					12,000
NEVADA | Industrial Building [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					expiring in 2024
Area of land					10,000
MOROCCO | Office Space [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					expiring in 2028
Area of land					10,000
Lease term extension option					option to extend the term for an additional five-year period
MARYLAND
Product Liability Contingency [Line Items]
Area of land					180,000
MARYLAND | Two Unit Apartment [Member]
Product Liability Contingency [Line Items]
Lessee, operating lease, description					expires in July 2022
Area of land					2,700

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	1 Months Ended
	Apr. 30, 2022$ / sharesshares
Subsequent Event [Line Items]
Share price | $ / shares	$ 13,500,000
Number of warrants exercised	750,000
Warrant exercise price | $ / shares	$ 0.50
Number of shares surrender for warrants exercised	515,039
Shares issued for warrant exercised	234,961